

Complete Specifications Accepted

Copies of the specification and drawings (if any) can be obtained from the IPONZ website www.iponz.govt.nz.

At any time within 3 months from the date of issue of this *Journal*, any person interested may give notice of opposition to the grant of a patent on any of the applications relating to the accepted complete specification shown hereunder, by filing form 15 in duplicate accompanied by a statement of the case in duplicate and a fee of \$300 plus GST where applicable, provided that if an application for extension on form 16 is made within the said 3 months, the Commissioner may extend the prescribed period for opposition to 4 months from the date of issue of this *Journal*. The grounds for giving notice of opposition are specified in section 21 of the Act, and prospective opponents should also refer to regulations 48 to 56 of the Patents Regulations 1954.

(21) 529231 (22) 2 May 2002

(54) Once-a-day oxycodone formulations

(86) PCT/US02/14024 (87) WO02/087512

(51) IPC7:A61K9/22,24,26,30,32,36

(71) Euro-Celtique s.A.

(72) Oshlack, Benjamin; Wright, Curtis; Prater, Derek;

(31) 01 288211 (32) 2 May 2001 (33) US

(74) JAMES & WELLS, Level 12, KPMG Centre, 85 Alexandra Street, Hamilton, New Zealand

(57) Disclosed is a sustained release osmotic oral dosage form comprising:

(a) a bilayer core comprising: (i) a drug layer comprising from about 1 mg to about 640 mg oxycodone or a pharmaceutically acceptable salt thereof; and (ii) a displacement layer comprising an osmopolymer; and

(b) a semipermeable wall surrounding the bilayer core having a passage-way disposed therein for the release of said oxycodone or pharmaceutically acceptable salt thereof; said dosage form providing an analgesic effect for at least about 24 hours and a mean C24/Cmax oxycodone ratio of 0.6 to 1.0 after once-a-day oral administration at steady state to human patients.

Divisional filed as 576494

(21) 531882 (22) 13 Sep 2002

(54) Recombinant plant allergens with reduced IgE binding while retaining T-cell antigenicity, which are useful in the immunomodulation of type I allergic disease conditions

(86) PCT/AU2002/01261 (87) WO2003/025009

(51) IPC7:C07K14/415; C07K16/16

(71) The University of Melbourne

(72) Deweerdt, Nicole; Singh, Mohan Bir; Bhalla, Prem L; Swoboda, Ines;

(31) 01 7792 (32) 20 Sep 2001 (33) AU

(74) DAVIES COLLISON CAVE - MELBOURNE, 1 Nicholson Street, Melbourne, Victoria, Australia

(57) The present disclosure relates generally to reagents useful in the immunotherapeutic or immunoprophylactic treatment of allergic diseases. More particularly, disclosed are recombinant pollen allergen 5 variants of the Lolium perene, Phleum pratense and Poa pratense species. The recombinant allergens exhibit reduced IgE interactivity including reduced IgE production-stimulatory activity, while retaining T-cell antigenicity, which are useful in the immunomodulation of type I allergic disease conditions. Further disclosed is the use these allergens in the manufacture of a medicament for the immunomodulation of allergic diseases such as type I allergic disease conditions.

Divisional filed as 572653

(21) 533548 (22) 4 Dec 2002

(54) Method and apparatus for treatment of a rotor blade on a windmill

(86) PCT/DK2002/000823 (87) WO2003/048569

(51) IPC7:F03D11/02; F03D1/06; B66F11/04

(71) PP ENERGY APS

(72) Teichert, Paul;


(31) 01 01817 (32) 6 Dec 2001

(33) DK

(31) 02 00014 (32) 4 Jan 2002 (33) DK

(74) PIPERS, Level 1, 5A Pacific Rise, Mt Wellington, Auckland, New Zealand

(57) Method and apparatus for treatment of a surface of a rotor blade of a windmill, whereby a rotor blade is positioned in an immobile position; an apparatus is mounted onto the rotor blade, the apparatus comprising means for surface treatment of the rotor blade; the apparatus is placed in such a manner that it can be moved in relation to the surface of the rotor blade; the apparatus is moved lengthwise along the rotor blade while engaging the rotor blade to directionally guide movement of the apparatus along the rotor blade, and whereby the apparatus is moved in a manner that accords with a treatment form that is carried out on the rotor blade.



(21) 539630 (22) 31 Oct 2003

(54) Layered packaging cushion, method of manufacture and machine for construction of cushion made up of layers of cellular material cut to conform to the item to be packaged

(86) PCT/US2003/034691 (87) WO2004/041659

(51) IPC7:B65D81/107,113


(71) SEALED AIR CORPORATION (US)

(72) De Luca, Nicholas P;

(31) 02 423267 (32) 31 Oct 2002 (33) US


(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) A packaging cushion insert (6) is disclosed. The insert (6) is useful for cushioning a packaged object. The insert is assembled from a top sheet (102), a bottom sheet (104) and a plurality of interior sheets (9) between the top (102) and bottom (104) sheets. The top sheet (102), the bottom sheet (104), and the plurality of interior sheets (9) are stacked and laminated. The sheets are each manufactured from one or more materials selected from an air-cellular cushioning material, cellular foam material, and crumpled paper material. The various sheets maybe pre-cut to conform to a particular cross-section of the object to be packaged before being laminated together to form voids (13) in the insert, into which the object or part of the object is placed.



(21) 540288 (22) 24 Nov 2003
 (54) Target for therapy of cognitive impairment
 (86) PCT/US2003/038191 (87) WO2004/048551
 (51) IPC7:C12Q1/68; C07H21/00; A01N43/04
 (71) THE JOHNS HOPKINS UNIVERSITY
 (72) Gallagher, Michela; Lund, Pauline Kay;
 (31) 02 428229 (32) 22 Nov 2002 (33) US
 (74) BALDWIN'S INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand
 (57) Provided is the use of valproic acid and related compounds for preparation of a medicament for treating Mild Cognitive Impairment (MCI) in a mammal, including human.
 Divisional filed as 565604

(21) 540303 (22) 29 Jul 2004
 (54) Method and system for identity recognition
 (86) PCT/US2004/024370 (87) WO2005/045579
 (51) IPC7:H04L9/32
 (71) MICROSOFT CORPORATION
 (72) Cameron, Kim; Nanda, Arun; Hacherl, Donald J; Satagopan, Murli; Kwan, Stuart; Brace, Colin; Smith, Walter; Dunn, Melissa;
 (31) 03 693172 (32) 23 Oct 2003 (33) US
 (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand
 (57) A method of sending an identity information document from an initiating system to an intended receiving system is provided. The method comprises:
 presenting a list of identity information from a self-identity information store for a principal using the initiating system to select information to include in the identity information document based on the intended receiving system, to allow the principal to control the disclosure of identity information to the intended receiving system;
 selecting identity information from the list of identity information from the self-identity information store stored in a memory for inclusion in the identity information document, wherein the selected identity information comprises a subset of identity information relating to the principal in the self-identity store and wherein the subset of identity information is specific to the intended receiving system;
 reading the selected identity information from a self-identity information store;
 generating the identity information document to include the selected identity information and at least a first key, the identity information document signed using a second key associated with the first key in the identity information document; and sending the identity information document to the receiving system.



(21) 541749 (22) 28 Jan 2004
 (54) Process for producing coated preparation comprising pioglitazone hydrochloride and a coating material
 (86) PCT/JP2004/000754 (87) WO2004/067001
 (51) IPC7:A61K31/439,155; A61K9/30; A61P3/10
 (71) Takeda Pharmaceutical Company Limited
 (72) Ohkouchi, Kazuhiro; Koike, Masahiko; Koyama, Hiroyoshi; Hamaguchi, Naoru;
 (31) 03 020925 (32) 29 Jan 2003 (33) JP
 (31) 03 276894 (32) 18 Jul 2003 (33) JP
 (31) 04 001128 (32) 6 Jan 2004 (33) JP
 (74) BALDWIN'S INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand
 (57) A production method of a coated preparation, which comprises coating with an aqueous dispersion of pioglitazone hydrochloride comprising a coating material selected from the group consisting of
 (a) hydroxypropyl cellulose whose 5 percent (w/v) aqueous solution has a viscosity of 24 mPa.s at 20 degrees Celsius and/or 2 percent (w/v) aqueous solution has a viscosity of 3.0-5.9 mPa.s at 20 degrees Celsius;
 (b) hydroxypropyl cellulose whose 5 percent (w/v) aqueous solution has a viscosity of 8 mPa.s at 20 degrees Celsius and/or 2 percent (w/v) aqueous solution has a viscosity of 2.0-2.9 mPa.s at 20 degrees Celsius; and
 (c) polyvinyl alcohol-polyethylene glycol graft copolymer whose 5 percent (w/v) aqueous solution has a viscosity of not more than 35 mPa.s at 20 degrees Celsius.

(21) 541928 (22) 24 Feb 2004
 (54) Remedy for spinal injury containing interleukin-6 antagonist
 (86) PCT/JP2004/002111 (87) WO2004/073741
 (51) IPC7:A61K45/00; A61K39/395; A61P19/00; A61P25/00; A61P43/00
 (71) CHUGAI SEIYAKU KABUSHIKI KAISHA

(72) Okano, Hideyuki; Okada, Seiji; Nakamura, Masaya; Yoshizaki, Kazuyuki;

(31) 03 046214 (32) 24 Feb 2003 (33) JP

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is the use of an antibody against interleukin-6 (IL-6) receptor for the manufacture of a therapeutic agent for spinal cord injury.

(21) 541973 (22) 10 Mar 2004

(54) Immunomodulating heterocyclic compounds

(86) PCT/GB2004/001008 (87) WO2004/081011

(51) IPC7:C07D487/04; C07D519/00; A61P3/10; A61P17/06; A61P19/02; A61P37/00; A61K31/5025

(71) MediGene Limited


(72) Mathews, Ian Richard;

(31) 03 0305876 (32) 14 Mar 2003 (33) GB

(31) 03 0319429 (32) 19 Aug 2003 (33) GB

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is a compound of formula (I) or a pharmaceutically of veterinarily acceptable salt, hydrate or solvate thereof: wherein X represents a bond or a divalent radical of formula $-(Z)n-(Alk)-$ or $-(Alk)-(Z)n$ wherein Z represents $-O-$, $-S-$ or $-NH-$, Alk is defined in relation to R₆, n is 0 or 1 and the rest of the substituents are disclosed within the specification. Disclosed is the use of the above compound in the manufacture of a medicament for the treatment of conditions which benefit from immunomodulation.



(21) 542134 (22) 4 Mar 2004

(54) Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells

(86) PCT/US2004/006570 (87) WO2004/091543

(51) IPC7:A61K39/395,40,42; C07K16/00

(71) ALEXION PHARMACEUTICALS, INC.

(72) Bowdish, Katherine S; Kretz-Rommel, Anke; Dakappagari, Naveen;

(31) 03 451816 (32) 4 Mar 2003 (33) US

(31) 03 529500 (32) 15 Dec 2003 (33) US

(31) 04 548385 (32) 28 Feb 2004 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Provided is the use, in the preparation of a medicament for treating autoimmune disease, of an antibody/autoantigen construct containing an autoantigen linked to an antibody to a receptor of an antigen presenting cell, wherein said receptor is selected from the group consisting of DEC-205, mannose receptor, DC-SIGN, DC-SIGNR, MHC, langerin, asialoglycoprotein receptor, beta-glucan receptor, C-type lectin receptor and dendritic cell immunoreceptor. Also provided are corresponding antibody/peptide constructs and methods of recombinantly producing such engineered antibodies.

Divisional filed as 577166

(21) 542787 (22) 2 Mar 2004

(54) Filtration, flow distribution and catalytic method for process streams using reticulated material that may have with a void space between them

(86) PCT/US2004/006366 (87) WO2004/094039

(51) IPC7:B01D46/42; B01J39/20


(71) Crystaphase International, Inc.

(72) Glover, John N;

(31) 03 396851 (32) 25 Mar 2003 (33) US

(74) Shelston IP, Level 21, 60 Margaret Street, Sydney, NSW 2000, Australia

(57) A method for removing contaminants from a process stream (20) is disclosed. The method includes the use of reticulated material (26, 28, 40, 42) to filter the process stream (20). The reticulated material (26, 28, 40, 42) also facilitates process stream flow distribution in process units (22). The reticulated material (26, 28, 40, 42) can be packed with a void space between a substantial number of the reticulated material (26, 28, 40, 42) that can be varied to enhance filtration and flow distribution. The method of filtering also provides a method of removing contaminants leaving process equipment. The methods can be used on a variety of process streams (20) and process equipment (22). The reticulated material (26, 28, 40, 42) can include ceramics, metallic materials, and chemical vapour deposition elements. The reticulated material (26, 28, 40, 42) can be of various shapes and sizes, and can also be catalytically active.



(21) 542886 (22) 14 May 2004

(54) Treatment of T-cell mediated diseases

(86) PCT/US2004/015340 (87) WO2004/103304

(51) IPC7:A61K38/00; A61K31/495

(71) DMI Biosciences, Inc.

(72) Bar-Or, David; Bar-Or, Raphael; Shimonkevitz, Richard;

(31) 03 471017 (32) 15 May 2003 (33) US

(31) 03 489270 (32) 21 Jul 2003 (33) US


(31) 03 514930 (32) 27 Oct 2003 (33) US

(31) 03 517338 (32) 4 Nov 2003 (33) US

(74) JAMES & WELLS, Level 12, KPMG Centre, 85 Alexandra Street, Hamilton, New Zealand

(57) Compounds of formula 1(I), wherein the substituents are as defined in the specification, can be used in the manufacture of a medicament for treating a T-cell mediated disease. Certain novel compounds of formula 1(I) are also disclosed.


Divisional filed as 576931



(21) 543288 (22) 30 Apr 2004
 (54) Thermogelling polymer blends for biomaterial applications
 (86) PCT/US2004/013343 (87) WO2004/098756
 (51) IPC7:A61F2/02; A61L31/04
 (71) DREXEL UNIVERSITY; SYNTHES GMBH
 (72) Lowman, Anthony M; Marcolongo, Michele S; Clemow, Alastair J T;
 (31) 03 466819 (32) 30 Apr 2003 (33) US
 (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand
 (57) Disclosed is a thermogelling hydrogel comprising a polymer blend comprising poly(N-isopropyl acrylamide) and a second polymer selected from the group consisting of poly(ethylene glycol), poly(vinyl pyrrolidone) and poly(vinyl alcohol); wherein said polymer blend solidifies from a liquid at room temperature to form a solid hydrogel implant at physiological body temperature.

(21) 543321 (22) 27 May 2004
 (54) Antifoaming formulations
 (86) PCT/US2004/016714 (87) WO2004/105914
 (51) IPC7:B01D12/00; B01D19/04
 (71) SYNGENTA LIMITED
 (72) Formstone, Carl; Hogbin, James; Landham, Rowena; Lipin, Daniel; Sohm, Rupert;
 (31) 03 0312195 (32) 28 May 2003 (33) GB
 (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand
 (57) Disclosed is an aqueous concentrate composition, comprising a water-insoluble liquid silicone-containing antifoaming agent, such as a polyalkylsilicone, in an organic solvent selected from alkyl, aralkyl and aryl esters of organic acids.

(21) 543355 (22) 26 May 2004
 (54) Crystalline form of the Beta 2 adrenergic receptor agonist N-[2-[4-((R)-2-hydroxy-2-phenylethylamino)phenyl]ethyl]-((R)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine monohydrochloride
 (86) PCT/US2004/016602 (87) WO2004/106279
 (51) IPC7:C07C233/43; A61K31/167; A61P11/08
 (71) THERAVANCE, INC.
 (72) Stergiades, Ioanna; Yost, Edward; Hubbard, Cristin; Zhang, Weijiang;
 (31) 03 473423 (32) 27 May 2003 (33) US
 (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand
 (57) Disclosed is the crystalline monohydrochloride salt of N-[2-[4-((R)-2-hydroxy-2-phenylethylamino)phenyl]ethyl]-((R)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine (Formula I). Further disclosed are pharmaceutical compositions which comprise a therapeutically effective amount of the above compound. A process for preparing the monohydrochloride salt of the compound of formula I is also disclosed, as is the use of the monohydrochloride salt of formula I in the manufacture of a medicament for treating a disease or condition associated with b2 adrenergic receptor activity in a mammal. The use of the medicament for treating pulmonary diseases such as asthma or chronic obstructive pulmonary disease is further disclosed.



(21) 543412 (22) 14 Apr 2004
 (54) Method of producing copper hydroxosulphates and copper fungicidal compositions containing same
 (86) PCT/FR2004/000913 (87) WO2004/094315
 (51) IPC7:C01G3/10,00; A01N59/20
 (71) CEREXAGRI S.A.
 (72) Joncheray, Gerard; Pillot, Marc; Ferrier, Frederic;
 (31) 03 0304784 (32) 16 Apr 2003 (33) FR
 (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand
 (57) Disclosed is a process of manufacturing aqueous suspensions of brochantite (Cu₄(OH)₆SO₄), or antlerite (Cu₃(OH)₄SO₄), or a mixture, wherein an aqueous solution of copper sulphate CuSO₄ with a concentration by weight of copper between 6% and 10% is reacted with an aqueous suspension of copper oxide or copper hydroxide with a concentration of between 15% and 50% by weight, wherein the molar ratio of SO₄/Cu is between 0.25 and 0.40, and where the reaction is carried out at a controlled temperature of between 40°C and 100°C. Also disclosed is the use of such suspensions in cupric fungicidal compositions, for the fungicidal treatment of crops.

(21) 543415 (22) 24 Apr 2004
 (54) Agents for controlling parasites on animals
 (86) PCT/EP2004/004359 (87) WO2004/098290
 (51) IPC7:A01N53/00; A01N51/00; A01N47/40; A01N37/32
 (71) Bayer HealthCare AG
 (72) Sirinyan, Kirkor; Turberg, Andreas;
 (31) 03 0320505 (32) 8 May 2003 (33) DE
 (74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand
 (57) Disclosed is a composition for controlling parasites on an animal, comprising
 a) flumethrin, cyfluthrin or beta-cyfluthrin
 b) MGK 264
 in a weight ratio of components a:b of at least 1:30.

(21) 543652 (22) 19 May 2004
 (54) Drug delivery system for female contraception and/or hormone replacement therapy
 (86) PCT/EP2004/050850 (87) WO2004/103336
 (51) IPC7:A61K9/00,24; A61K31/565; A61P15/18; A61P31/18
 (71) N.V. Organon
 (72) Groenewegen, Rudolf Johannes Joseph; De Graaff, Wouter; Out, Henk Jan;
 (31) 03 03101490 (32) 23 May 2003 (33) EP
 (31) 03 473055 (32) 23 May 2003 (33) US
 (74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand
 (57) Disclosed is a drug delivery system comprising at least one compartment consisting of (i) a drug-loaded thermoplastic polymer core, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said intermediate layer is loaded with (a) crystals of a first pharmaceutically active compound and with (b) a second pharmaceutically active compound in dissolved form and wherein said core is loaded with said second compound in dissolved form. Also disclosed is a method of contraception which comprises the steps of (i) positioning the drug deliv-

ery system within the female vaginal tract and (ii) retaining the system within the vaginal tract for at least about 21 days. Use of the drug delivery system for the manufacture of a medicament for hormone replacement therapy is further disclosed, as is the use of the drug delivery system for the manufacture of a combination preparation to provide contraception and to treat and/or prevent a sexually transmitted disease.

(21) 543714 (22) 14 Jun 2004

(54) Processes for the preparation of 1-[(benzoimidazol-1-yl)quinolin-8-yl]piperidin-4-ylamine derivatives

(86) PCT/IB2004/001983 (87) WO2004/113322

(51) IPC7:C07D401/14; C07D215/38; C07D305/06; C07D215/24,44

(71) PFIZER PRODUCTS INC.


(72) Tom, Norma Jacqueline; Ripin, David Harold Brown; Castaldi, Michael James;

(31) 03 482176 (32) 24 Jun 2003 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is a process for preparing compounds of formula I, wherein the substituents are as defined in the specification, said process comprising reacting a compound of formula II, wherein BOC is t-butoxycarbonyl, with a metal alkoxide in the presence of water.

Divisional filed as 571898



(21) 543805 (22) 10 Jun 2004

(54) 1-(Alkylaminoalkyl-pyrrolidinyl/piperidinyl)-2,2-diphenylacetamide derivatives as muscarinic receptor antagonists

(86) PCT/US2004/018813 (87) WO2005/003090

(51) IPC7:C07D207/08; C07D211/34; A61K31/40; A61P11/06


(71) THERAVANCE, INC.

(72) Mammen, Mathai; Hughes, Adam; Ji, Yu-Hua; Li, Li; Zhang, Weijiang;

(31) 03 478456 (32) 13 Jun 2003 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is a compound of formula (I), with substituents as defined in the specification, and pharmaceutically acceptable salts thereof. Also disclosed is the use of the compound to treat a pulmonary disorder such as chronic obstructive pulmonary disease (COPD) or asthma. Also disclosed is a synthesis for the compound.



(21) 543993 (22) 6 May 2004

(54) Preparation and use of aryl alkyl acid derivatives for the treatment of obesity

(86) PCT/US2004/014036 (87) WO2004/100881

(51) IPC7:C07D235/30; A61K31/4168; C07D233/88; C07D263/48; C07D277/38; C07D263/58; C07D277/82


(71) BAYER PHARMACEUTICALS CORPORATION

(72) Smith, Roger; Campbell, Ann-Marie; Coish, Philip; Dai, Miao; Jenkins, Susan; Lowe, Derek; O'Connor, Stephen; Su, Ning; Wang, Gan; Zhang, Mingbao; Zhu, Lei;

(31) 03 469619 (32) 9 May 2003 (33) US

(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand

(57) Disclosed are compounds of formulae (I), (Ia), (Ib) and (VIII), wherein the substituents are as defined in the specification; processes for their preparation and their utility as agents for treating or preventing obesity and related diseases such as dyslipidemia, cholesterol gallstones, gall-bladder disease, gout, cancer, menstrual abnormalities, infertility, polycystic ovaries, osteoarthritis, sleep apnea, hypertriglyceridemia, Syndrome X, type 2 diabetes, atherosclerotic diseases, hyperlipidemia, hypercholesteremia, low HDL levels, hypertension, cardiovascular disease, coronary heart disease, coronary artery disease, cerebrovascular disease, stroke, and peripheral vessel disease.



(21) 544024 (22) 12 May 2004

(54) Novel poly(ethylene glycol) modified compounds and uses thereof

(86) PCT/US2004/014888 (87) WO2004/101600

(51) IPC7:C07K1/107; C07K14/505; A61K38/18,19

(71) Affymax, Inc.

(72) Holmes, Chris; Yin, Kevin; Tumelty, David; Lalonde, Guy; Balu, Palani; Schatz, Peter;

(31) 03 470246 (32) 12 May 2003 (33) US

(74) JAMES & WELLS, Level 12, KPMG Centre, 85 Alexandra Street, Hamilton, New Zealand

(57) Provided is a peptide based compound comprising (a) a peptide moiety that binds to an erythropoietin receptor, said peptide moiety having an N-terminus and a C-terminus; and (b) at least one linear poly(ethylene glycol) attached to the C-terminus of the peptide moiety and having a molecular weight of 20 KDaltons or more, wherein the peptide moiety is: (i) a peptide monomer comprising no more than 50 amino acids; or (ii) a peptide dimer comprising two peptide monomers, each peptide monomer of the peptide dimer comprising no more than 50 amino acids.

(21) 544163 (22) 2 Jun 2004

(54) Complement inhibitors

(86) PCT/GB2004/002341 (87) WO2004/106369

(51) IPC7:C12N15/12; C07K14/435; C12N15/11,62; A61K38/17; G01N33/68

(71) EVOLUTEC LIMITED

(72) Nunn, Miles Andrew;

(31) 03 0312619 (32) 2 Jun 2003 (33) GB

(31) 03 0327386 (32) 25 Nov 2003 (33) GB

(74) BALDWIN'S INTELLECTUAL PROPERTY, Level 14, Baldwin's Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) Provided is a complement inhibitor polypeptide derived from tick saliva that inhibits the classical complement pathway and the alternative complement pathway by inhibiting cleavage of C5 by classical and alternative C5 convertases, wherein said complement inhibitor has a specified sequence or at least 70% identity thereto. Further provided are active fragments of said proteins, antibodies binding the proteins, DNAs

encoding the proteins and uses of these material to produce the proteins and to vaccinate non-human animals and to inhibit the complement pathways in non-human cells, tissues or organisms.

(21) 544231 (22) 4 Jun 2004

(54) Process for the preparation of substituted 3-aryl-butyl-amine compounds

(86) PCT/EP2004/006027 (87) WO2004/108658

(51) IPC7:C07C217/62; C07C211/27,28

(71) Grunenthal GmbH

(72) Hell, Wolfgang; Kegel, Markus; Akteries, Bernhard; Buschmann, Helmut; Holenz, Jorg; Lobermann, Hartmut; Heller, Detlef; Drexler, Hans-Joachim; Gladow, Stefan;

(31) 03 0326097 (32) 6 Jun 2003 (33) DE




(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) Disclosed is a process for the preparation of a substituted 3-aryl-butyl-amine compound of the general formula I wherein

R7 and R8 in each case independently of one another are chosen from H or C1-3-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted, and wherein the rest of the substituents are disclosed within the specification, in each case in the form of a pure stereoisomer, racemate or in the form of a mixture of stereoisomers in any desired mixing ratio, or in each case in the form of a physiologically acceptable salt, or in each case in the form of a solvate,

in which a first step a) a 1-amino-3-aryl-butan-3-ol compound of the general formula II wherein the substituents are defined within the specification and in each case optionally in the form of a pure stereoisomer, racemate or in the form of a mixture of stereoisomers in any desired mixing ratio, or in each case in the form of a physiologically acceptable salt, or in each case in the form of a solvate, is employed and elimination is carried out under the action of an acid to give a substituted 3-aryl-but-3-enyl-amine compound of the general formula III wherein the substituents are disclosed in the specification, in each case optionally in the form of a pure stereoisomer, racemate or in the form of a mixture of stereoisomers in any desired mixing ratio, or in each case in the form of a physiologically acceptable salt, or in each case in the form of a solvate,

and in a second step b) the substituted 3-aryl-but-3-enyl-amine compound according to the general formula III formed is then hydrogenated under the participation of a metal catalyst and hydrogen to give a substituted 3-aryl-butyl-amine compound of the general formula I.



(21) 544262 (22) 23 Jul 2004

(54) Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands

(86) PCT/US2004/023794 (87) WO2005/012306

(51) IPC7:C07D487/04; A61K31/519

(71) Neurogen Corporation

(72) Xie, Linghong; Han, Bingsong; Xu, Yuelian; Maynard, George; Chenard, Bertrand L; Shaw, Kenneth; Gao, Yang;


(31) 03 490006 (32) 25 Jul 2003 (33) US

(31) 04 543083 (32) 9 Feb 2004 (33) US

(74) Pizzzeys Patent and Trade Mark Attorneys, Level 14, ANZ Centre, 324 Queen Street, Brisbane, Queensland 4000, Australia

(57) Disclosed is a compound of formula I or a pharmaceutically acceptable salt thereof, wherein Z1 is nitrogen or CR1, Z2 is nitrogen or CR2, Z3 is nitrogen or CR3, such that at least one, but no more than two, of Z1, Z2 and Z3 are nitrogen; and wherein the rest of the substituents are disclosed within the specification.

Also disclosed is the suitability of the above compound for treating central nervous system (CNS) diseases.



(21) 544330 (22) 25 Jun 2004

(54) Sulfonamide substituted imidazoquinolines

(86) PCT/US2004/020607 (87) WO2005/003065

(51) IPC7:A61K31/4745; C07D471/04; A61P31/12; A61P35/00


(71) 3M INNOVATIVE PROPERTIES COMPANY

(72) Greisgraber, George W;

(31) 03 483200 (32) 27 Jun 2003 (33) US

(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand

(57) Disclosed is N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide, a compound useful in the treatment of viral and neoplastic diseases.



(21) 544391 (22) 7 Jun 2004

(54) Plant transformation and selection

(86) PCT/US2004/018024 (87) WO2004/108903

(51) IPC7:A01H5/00; C12N15/84,82; A01H1/00

(71) ArborGen, LLC

(72) Handley, Levis W; Connett, Marie B; Chang, Shujun; Thomas, Robert D; Hamilton, Randy L;

(31) 03 476222 (32) 6 Jun 2003 (33) US

(31) 03 476238 (32) 6 Jun 2003 (33) US

(74) KNIGHTSBRIDGE PATENT ATTORNEYS, Level 14, 200 Queen Street, Melbourne, Victoria 3000, Australia

(57) Disclosed is a shoot regeneration medium composition comprising a sulfonylurea or imidazolinone herbicide and a derivative of casein hydrosylate, where the medium is substantially free of branched chain amino acids. The shoot regeneration medium is useful as a selection medium in producing a transgenic plant.

(21) 544451 (22) 30 Jun 2004

(54) Uses of a novel eimeria gene and corresponding protein

(86) PCT/EP2004/007080 (87) WO05/005472

(51) IPC7:C07K14/44; A61K39/395,012; C12N15/30

(71) BAYER HEALTHCARE AG

(72) Greif, Gisela; Hosse, Ralf; Krucken, Jurgen; Wunderlich, Frank;

(31) 03 0330235 (32) 4 Jul 2003 (33) DE

(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand

(57) Disclosed is a polynucleotide encoding an oocyst sporocyst protein of *Eimeria tenella* comprising:

a) the sequence of SEQ ID NO: 1;

b) a polynucleotide which exhibits a sequence identity of more than 95% with the polynucleotide having the sequence of SEQ ID NO: 1;

c) a polynucleotide which hybridizes, under highly stringent conditions, with the polynucleotide having the sequence of SEQ ID NO: 1; or,

d) a polynucleotide which differs from a polynucleotide having the sequence of SEQ ID NO: 1 due to the degeneracy of the genetic code.

Also disclosed are vectors and host cells comprising the polynucleotide described above.

(21) 544457 (22) 8 Jul 2004

(54) Gasoline compositions

(86) PCT/EP2004/051423 (87) WO05/014759

(51) IPC7:C10L1/14,18; C10L10/00,04; C10L1/02,22,06

(71) SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V.

(72) Groves, Adrian Philip; Morley, Christopher; Smith, Johanne;

(31) 03 03254454 (32) 15 Jul 2003 (33) EP

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is a gasoline composition comprising a major amount of a gasoline suitable for use in a spark ignition engine, 1 to 15% v of ethyl levulinate, and 20 to 2000 ppmw of a nitrogen-containing detergent containing a hydrocarbyl group having a number average molecular weight in the range 750 to 6000.

(21) 544576 (22) 9 Jul 2004

(54) Specific glucocorticosteroid compound having anti-inflammatory activity

(86) PCT/EP2004/007819 (87) WO2005/005451

(51) IPC7:C07J3/00; A61K31/56; A61P5/44; C07D239/20

(71) GLAXO GROUP LIMITED

(72) Biggadike, Keith; Needham, Deborah; John, Matthew Peter;

(31) 03 0316290 (32) 11 Jul 2003 (33) GB

(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand

(57) Disclosed is a compound of formula (I) wherein X represents O or S; and wherein the rest of the substituents are disclosed within or a physiologically acceptable salt or solvate thereof.

Also disclosed is the use of the above compound of formula (I) or a physiologically acceptable solvate thereof for the manufacture of a medicament for the treatment of inflammatory and/or allergic conditions.

(21) 544607 (22) 14 Jun 2004

(54) Rope terminator using interlocking hollow conical wedges to trap and secure the fibers of the rope

(86) PCT/GB2004/002571 (87) WO2004/113760

(51) IPC7:F16G11/05

(71) Colt Systems Limited

(72) Pearce, Colin Richard; Farrelly, Justin Nicolas;

(31) 03 0313880 (32) 14 Jun 2003 (33) GB

(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) A connector assembly (30) for preventing sealing connection with a non-permitted, substantially uniform internal diameter conduit having an end face is disclosed. The connector assembly (30) comprises a first connector (36) having a floor (46) and a coupling portion (42). The coupling portion (42) projects outward from the floor (46), the coupling portion (42) including a sealing surface (48) and a non-sealing surface (52), the non-sealing surface (52) being located closer to a free end (44) of the first connector (36) than the sealing surface (48), the non-sealing surface (52) being sized and shaped to hold the non-permitted conduit off of the sealing surface (48) and prevent sealing therewith through the action of the passages (58). A bleed passage (60) is located generally adjacent the floor (46) for bleeding fluid out of the connector assembly (30).



(21) 544647 (22) 2 Jul 2004

(54) Use of spirodiclofen in order to combat acarides

(86) PCT/EP2004/007225 (87) WO2005/004605

(51) IPC7:A01N43/08


(71) Bayer CropScience AG

(72) Fischer, Reiner; Bruck, Ernst;

(31) 03 0331674 (32) 14 Jul 2003 (33) DE

(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand

(57) Disclosed is the use of the compound of formula (I) for controlling acarids in soft fruits, such as currant, gooseberry, raspberry, blackberry, strawberry, and blueberry.



(21) 544687 (22) 21 Jun 2004

(54) Treatment of amyloid- and epileptogenesis-associated diseases

(86) PCT/US2004/019839 (87) WO2005/000406

(51) IPC7:A61P25/08,14,16,18,22,28; A61P27/00; A61P29/00; A61K31/185; C07C309/14,19,24,69; C07D521/00

(71) BELLUS Health (International) Limited

(72) Kong, Xianqi; Lu, Wenshuo; Wu, Xinfu;


(31) 03 480928 (32) 23 Jun 2003 (33) US

(31) 03 512018 (32) 17 Oct 2003 (33) US

(31) 04 871512 (32) 18 Jun 2004 (33) US

(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) Disclosed is a compound of formula (I) and pharmaceutically acceptable salts thereof, where X is oxygen or nitrogen, Z is S(O)₂, m and n are between 0 and 10, and where the rest of the substituents are defined in the specification. Also disclosed is the use of the compound to treat or prevent Alzheimer's disease.



(21) 544718 (22) 2 Jul 2004

(54) Pharmaceutical formulations for intranasal administration of protein comprising a chitosan or a derivative thereof

(86) PCT/GB2004/002876 (87) WO2005/004838

(51) IPC7:A61K9/00; A61K38/27; A61P43/00

(71) ARCHIMEDES DEVELOPMENT LIMITED

(72) Dyer, Ann Margaret; Watts, Peter James; Cheng, Yu-Hui; Smith, Alan;

(31) 03 0315632 (32) 4 Jul 2003 (33) GB

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is a powder formulation for intranasal delivery comprising a protein having a molecular weight of 10 kDa or greater and chitosan, wherein the formulation has a mean particle size, expressed as the volume mean diameter (D50%), of from 25 to 200 micrometres. Preferably the protein is human growth hormone.

(21) 544747 (22) 6 Jul 2004

(54) Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists

(86) PCT/US2004/021593 (87) WO2005/007165

(51) IPC7:A61K31/513; C07D239/54; C07D401/12; C07D405/04; A61P5/02


(71) NEUROCRINE BIOSCIENCES INC

(72) Guo, Zhiqiang; Chen, Yongsheng; Wu, Dongpei; Chen, Chen; Wade, Warren; Dwight, Wesley J; Huang, Charles Q; Tucci, Fabio C;

(31) 03 485434 (32) 7 Jul 2003 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed are compounds of the following formula, wherein the substituents are as defined in the specification. The compounds are GnRH receptor antagonists useful in the treatment of a variety of sex-hormone related conditions in both men and women, such as benign prostatic hypertrophy or myoma of the uterus, cancer including prostatic cancer, uterine cancer, breast cancer or pituitary gonadotroph adenomas, endometriosis, polycystic ovarian disease, uterine fibroids, precocious puberty, infertility, lupus erythematosus, irritable bowel syndrome, premenstrual syndrome, hirsutism, short stature and sleep disorders.



(21) 544750 (22) 28 Jun 2004

(54) Compositions of amphomycin or aspartocin based lipopeptide antibiotic derivatives and methods of use thereof

(86) PCT/US2004/021039 (87) WO2005/000878

(51) IPC7:C07K7/56; A61K38/12; A61P31/04

(71) MIGENIX INC.


(72) Cameron, Dale R; Boyd, Vincent A; Leese, Richard A; Curran, William V; Borders, Donald B; Wacowich-Sgarbi, Shirley A; Nodwell, Matthew; Chen, Yuchen; Jia, Qi; Dugourd, Dominique; Sgarbi, Paulo W M;

(31) 03 488331 (32) 17 Jul 2003 (33) US

(31) 04 564912 (32) 23 Apr 2004 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed are compounds of formula (II), wherein the substituents are as defined in the specification. The compounds are derivatives of lipopeptide antibiotics that display antimicrobial activity against microorganisms. Also disclosed are methods and compounds for synthesizing such antimicrobial derivatives and analogues, and methods of using the compounds in a variety of contexts, including in the treatment and prevention of microbial infections.



(21) 544801 (22) 4 Jun 2004

(54) Antiseptic compositions, methods and systems

(86) PCT/US2004/018009 (87) WO2004/108093

(51) IPC7:A61K31/195

(71) TYCO HEALTHCARE GROUP LP

(72) Kite, Peter; Hatton, David;

(31) 03 476274 (32) 4 Jun 2003 (33) US

(31) 03 659413 (32) 10 Sep 2003 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) An antiseptic composition adapted for medical or veterinary treatment comprising at least one salt of ethylene diamine tetraacetic acid (EDTA) in solution, wherein the at least one EDTA salt comprises at least one of tri-sodium and tetra sodium EDTA at a concentration of at least 0.01% (w/v) and less than 15% (w/v), wherein the antiseptic composition has a bactericidal effect over a broad spectrum of microbes, wherein the antiseptic composition has a pH of at least 9.5, and wherein the antiseptic composition is safe and biocompatible in a patient's bloodstream and packaged in a sterile, non-pyrogenic form.

(21) 544874 (22) 30 Jun 2004

(54) Fungicidal mixtures for controlling rice pathogens comprising triazolopyrimidine derivative and fenpropimorph

(86) PCT/EP2004/007075 (87) WO2005/004608

(51) IPC7:A01N43/90,84

(71) BASF Aktiengesellschaft

(72) Tormo I Blasco, Jordi; Grote, Thomas; Scherer, Maria; Stierl, Reinhard; Strathmann, Siegfried; Schofl, Ulrich;


(31) 03 0331452 (32) 10 Jul 2003 (33) DE

(31) 03 0332432 (32) 16 Jul 2003 (33) DE


(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) Disclosed is a fungicidal mixture, comprising the triazolopyrimidine derivative of formula I and fenpropimorph of formula II in a synergistically effective amount.

Also disclosed is a method for controlling harmful fungi which are rice pathogens, such as *Corticium sasakii*, which comprises treating the fungi, their habitat or the plants, the soil or the seeds to be protected against fungal attack with an effective amount of the above mixture.



- (21) 544875 (22) 30 Jun 2004
 (54) Fungicidal mixtures comprising triazolopyrimidine derivative and kresoxim-methyl
 (86) PCT/EP2004/007079 (87) WO2005/004609
 (51) IPC7:A01N43/90; A01N37/50
 (71) BASF Aktiengesellschaft
 (72) Blasco, Jordi Tormo i; Grote, Thomas; Scherer, Maria; Stierl, Reinhard; Strathmann, Siegfried; Schofl, Ulrich; Haden, Egon; Hampel, Manfred;
 (31) 03 0331117 (32) 9 Jul 2003 (33) DE
 (31) 03 0332460 (32) 16 Jul 2003 (33) DE
 (31) 04 04016084 (32) 30 Mar 2004 (33) DE
 (74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand
 (57) Disclosed is a fungicidal mixture, comprising the triazolopyrimidine derivative formula I and kresoxim-methyl of formula II in a synergistically effective amount.
 Also disclosed is a method for controlling harmful fungi which are rice pathogens, such as *Corticium sasakii*, which comprises treating the fungi, their habitat or the plants, the soil or the seed to be protected against fungal attack with an effective amount of the above mixture.




- (21) 544889 (22) 2 Jul 2004
 (54) Methods and means for regulating gene expression using CodY
 (86) PCT/NL2004/000474 (87) WO2005/003354
 (51) IPC7:C12N15/63,31; C12Q1/00; C12R1/23,46; A23C19/00; C12N15/74
 (71) Friesland Brands B.V.
 (72) Den Hengst, Christiaan Daniel; Gajic, Olivera; Kuipers, Oscar Paul; Kok, Jan; Sikkema, Jan; Geurts, Johannes Marie Wilhelmus; Nauta, Arjen;
 (31) 03 03077074 (32) 2 Jul 2003 (33) EP
 (74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand
 (57) Disclosed is a method for regulating the expression of a gene of interest in a host cell that comprises a CodY protein comprising providing said cell with a gene of interest in operable linkage with a promoter and at least one CodY target sequence, wherein the number of CodY target sequences is increased, resulting in more than one CodY target sequence, and wherein said at least one CodY target sequence com-

prises the sequence WHAATIDTCWGAHAAWTNNRWNADWW or AWTIDTCAGAAWWWT or AATITTCWGAAAATI or a sequence as depicted in Table 4, Table 4A, Table 5, Table 6, Table 7 and/or Table 8, wherein W = T or A, R = A or G, D = not C and H = not G, and provided that if the cell is a human cell, it is ex vivo.


- (21) 545048 (22) 6 Aug 2004
 (54) Chimeric antigens for breaking host tolerance to foreign antigens
 (86) PCT/CA2004/001469 (87) WO2005/014838
 (51) IPC7:C12P21/02; C07K16/28; A61K39/29; A61K47/48; A61P31/12,20
 (71) ViRexx Medical Corp.
 (72) Noujaim, Antoine; Wang, Dakun; George, Rajan; Tyrrell, Lorne; Ma, Allan;
 (31) 03 493449 (32) 8 Aug 2003 (33) US
 (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand
 (57) Provided is chimeric antigen for eliciting an immune response, the chimeric antigen comprising one or more antigen domains and an antigen presenting cell (APC) binding domain, wherein the one more antigen domains comprise at least one antigenic portion of a hepatitis B virus (HBV) surface antigen and wherein the APC binding domain comprises an antibody fragment consisting of an immunoglobulin heavy chain fragment. Further provided are pharmaceutical compositions comprising the antigen and polynucleotides coding for the antigen, methods of producing the antigen using vectors and use of the antigen in the preparation of a medicament for activating an APC, useful for treating parasitic or viral infections, including HBV.

- (21) 545049 (22) 3 Sep 2004
 (54) Substituted 2-carboxylamino-6-piperidinaminopyridines and substituted 1-carboxylamino-3-piperidinaminobenzenes as 5-HT1F agonists
 (86) PCT/US2004/025607 (87) WO2005/035499
 (51) IPC7:C07D211/58; C07D401/14,12; A61K31/444,4436,4439,4409
 (71) ELI LILLY AND COMPANY
 (72) Blanco-Pillado, Maria-Jesus; Cohen, Michael Philip; Filla, Sandra Ann; Hudziak, Kevin John; Kohlman, Daniel Timothy; Benesh, Dana Rae; Victor, Frantz; Xu, Yao-Chang; Ying, Bai-Ping; Zacherl, DeAnna Piatt; Zhang, Deyi; Mathes, Brian Michael;
 (31) 03 502780 (32) 12 Sep 2003 (33) US
 (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand
 (57) Disclosed are substituted 2-carboxylamino-6-piperidinaminopyridines and substituted 1-carboxylamino-3-piperidinaminobenzenes of formula I or a pharmaceutically acceptable acid addition salt thereof, where the substituents are as disclosed herein. The use of a compound of formula I in the manufacture of a medicament for the treatment or prevention of migraine in a mammal is further disclosed.




(21) 545134 (22) 17 Sep 2004
 (54) Modulation of eIF4E expression
 (86) PCT/US2004/030436 (87) WO2005/028628
 (51) IPC7:C12N15/11; A61K31/7088,713; A61P35/00; A61P9/00
 (71) ELI LILLY & COMPANY; ISIS PHARMACEUTICALS, INC.
 (72) Freier, Susan M; Dobie, Kenneth W; Marcusson, Eric G; Swayze, Eric E; Bhat, Balkrishen; Graff, Jeremy R; Konicek, Bruce W;
 (31) 03 504110 (32) 18 Sep 2003 (33) US
 (31) 04 576534 (32) 3 Jun 2004 (33) US
 (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand
 (57) Provided is a modified antisense oligonucleotide targeting eukaryotic initiation factor 4E (eIF4E), comprising a specified nucleotide sequence having at least one chemically modified sugar moiety, internucleoside linkage, or nucleobase, or a pharmaceutically acceptable salt thereof. Further provided are specific modified sugars in said oligonucleotides, pharmaceutical compositions comprising the oligonucleotides and use of the oligonucleotides for the manufacture of a medicament for the treatment of a condition or disease associated with eIF4E expression or overexpression.
 Divisional filed as 576775

(21) 545197 (22) 8 Jul 2004
 (54) Benzofuran derivatives and their use in the treatment of microbial infections
 (86) PCT/EP2004/007482 (87) WO2005/005418
 (51) IPC7:C07D407/14; A61K31/506; A61P31/04
 (71) ARPIDA AG
 (72) Greiveldinger-Poenaru, Sorana; Islam, Khalid; Gillesen, Dieter; Burri, Kaspar;
 (31) 03EP 0307537 (32) 11 Jul 2003 (33) EP
 (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand
 (57) Disclosed are compounds of the general formula I wherein R1 represents the group of formula II; R4 represents hydrogen; and wherein the rest of the substituents are disclosed within the specification and pharmaceutically acceptable salts thereof.
 Also disclosed is the use of one or more of the above compounds as active ingredients for the production of pharmaceutical compositions for the treatment of infections.



(21) 545216 (22) 26 Aug 2004
 (54) Caspase inhibitors containing isoxazoline ring
 (86) PCT/KR2004/002139 (87) WO2005/021516
 (51) IPC7:C07D261/04
 (71) LG Life Sciences Ltd

(72) Chang, Hye-Kyung; Oh, Yeong-Soo; Park, Cheol-Won; Jang, Yong-Jin; Park, Tae-Kyo; Kim, Sung-Sub; Kim, Min-Jung; Park, Mi-Jeong; Park, Jung-Gyu; Park, Hee-Dong; Min, Kyeong-Sik; Lee, Tae-Soo; Lee, Sang-Kyun; Kim, Soo-Hyeon; Jeong, Hee-Kyung; Lee, Sun-Hwa; Kim, Hwa-Dong; Kim, Ae-Ri; Park, Ki-Sook; Shin, Hyun-Ik; Choi, Hyeong-Wook; Lee, Kyu-Woong; Lee, Jae-Hoon; Heo, Tae-Ho; Kim, Ho-Jun; Kwon, Tae-Sik; Seong, Jeong Hui;
 (31) 03 0059451 (32) 27 Aug 2003 (33) KR
 (74) J D Hardie, 14th Floor, 44-48 Emily Place, Auckland, New Zealand
 (57) Disclosed is an isoxazoline derivative of formula 1 wherein the substituents are defined within the specification or a stereoisomer thereof. Also disclosed is the use of the caspase inhibitor of formula 1, salt, or stereoisomer thereof for preparing a therapeutic composition for preventing inflammation and apoptosis.



(21) 545318 (22) 15 Jul 2004
 (54) Pharmaceutical compositions for healing wounds comprising insulin and PKC alpha inhibitor
 (86) PCT/IL2004/000640 (87) WO2005/007072
 (51) IPC7:A61K31/74; A61P17/02
 (71) BAR-ILAN UNIVERSITY
 (72) Tennenbaum, Tamar; Sampson, Sanford; Kuroki, Toshio; Alt, Addy; Shen, Shlomzion;
 (31) 03 486906 (32) 15 Jul 2003 (33) US
 (31) 03 644775 (32) 21 Aug 2003 (33) US
 (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand
 (57) Disclosed is the use of insulin and at least one PKC alpha inhibitor acting in synergy with said insulin for the preparation of a pharmaceutical composition adapted for topical application for inducing or accelerating a healing process of a damaged skin or skin wound.
 Divisional filed as 573737

(21) 545339 (22) 30 Jul 2004
 (54) Process for preparation of flax protein isolate
 (86) PCT/CA2004/001433 (87) WO2005/012342
 (51) IPC7:C07K14/415; C07K1/14
 (71) BURCON NUTRASCIENCE (MB) CORP.
 (72) Green, Brent E; Milanova, Radka; Logie, James;
 (31) 03 491564 (32) 1 Aug 2003 (33) US
 (31) 03 516875 (32) 4 Nov 2003 (33) US
 (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand
 (57) Flax protein isolates are obtained in a procedure in which flax oil seeds are initially extracted to remove mucilage therefrom prior to crushing to recover the oil and produce a meal. The flax protein meal then is processed to recover a flax protein isolate therefrom, wherein the initial extraction of the flax seed at elevated temperature using a mildly-alkaline solution of sodium bicarbonate to remove mucilage results in the production of a much higher concentration of concentrated aqueous protein solution, enabling improved yields of flax protein isolate to be obtained. In addition, a flax protein isolate can be produced from flax protein meal by isoelectric precipitation or by a micellar route.

(21) 545341 (22) 30 Jul 2004
 (54) Biologically non-degradable peptide, angiotensin converting enzyme inhibitor, drug and functional food
 (86) PCT/JP2004/010929 (87) WO2005/012334
 (51) IPC7:C07K5/062,068,072,083; A61K37/64; A61P9/12; A23L1/305; A61K38/05; C07K5/06

(71) Calpis Co., Ltd.

(72) Yamamoto, Naoyuki; Mizuno, Seiichi; Nishimura, Shingo; Gotou, Takanobu; Matsuura, Keiichi;

(31) 03 285007 (32) 1 Aug 2003 (33) JP

(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) Disclosed is the use of a peptide having Pro at a carboxyl terminal, selected from the group consisting of Gln-Pro, Met-Pro, and Ser-Pro-Pro, or a salt thereof in the manufacture of a medicament or a functional food for reducing blood pressure.

(21) 545360 (22) 27 Aug 2004

(54) Interfering RNA duplex having blunt-ends and 3'-modifications

(86) PCT/EP2004/009599 (87) WO2005/021749

(51) IPC7:C12N15/11; A61K48/00


(71) Novartis AG

(72) Weiler, Jan; Hall, Jonathan; Bologna, Jean-Charles; Natt, Francois Jean-Charles; Haner, Robert;

(31) 03 498514 (32) 28 Aug 2003 (33) US

(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) Disclosed is a double-stranded RNA with at least one blunt end comprising at least one 3'-end of formula I wherein X is O or S, R1 and R2 are independently OH, NH2, SH, alkyl, aryl, alkyl-aryl or aryl alkyl, or R1 and R2 may be of formula Y-Z where Y is O, N or S and Z is H, alkyl, aryl, alkyl-aryl or aryl-alkyl. The dsRNA disclosed mediates RNA interference.



(21) 545364 (22) 23 Aug 2004

(54) HPV CD8+ T-cell epitopes

(86) PCT/US2004/027263 (87) WO2005/025497

(51) IPC7:C12Q1/68

(71) GENENCOR INTERNATIONAL, INC.

(72) Harding, Fiona A; Mucha, Jeanette Marie;

(31) 03 500452 (32) 5 Sep 2003 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Provided is a method for determining a CD8+ T-cell epitope in a protein, comprising the steps of: (a) differentiating a solution of dendritic cells and a solution of naïve CD8+ T-cells from a single human blood source obtained from a human to produce a solution of differentiated dendritic cells; (b) preparing a pepset of peptides from said protein, wherein said pepset comprises said T-cell epitope; (c) combining said solution of said CD8+ T-cells and an anti-CD40 antibody to provide a T-cell and antibody solution; (d) combining said differentiated dendritic cells with each peptide separately in said pepset with said T-cell and antibody solution; and (e) measuring the proliferation of said T-cells in said step (d), to identify said peptide as a CD8+ T-cell epitope wherein said protein is not a human papillomavirus (HPV) protein. Further provided are methods of reducing allergenicity or increasing immunogenicity of a protein comprising modifying such identified epitopes.

(21) 545470 (22) 4 Aug 2004

(54) Lipid system and methods of use

(86) PCT/US2004/025161 (87) WO2005/025334

(51) IPC7:A23L1/30,29

(71) ABBOTT LABORATORIES

(72) Mustad, Vikkie A; Demichele, Stephen; Zinker, Bradley A; Huang, Yung-Sheng;

(31) 03 656662 (32) 5 Sep 2003 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is a composition of omega-3, omega-6, and omega-9 fatty acids, where the ratio of omega-6 to omega-3 is between 0.25:1 and 3:1, the ratio of omega-9 to omega-3 is between 0.4:1 and 3:1, wherein the composition comprises 17-54% of the omega-3 fatty acid alpha-linolenic acid, 17-21% of the omega-6 fatty acid linoleic acid, and 19-52% if the omega-9 fatty acid oleic acid. Also disclosed in the use if this composition to improve glucose tolerance in glucose intolerant individuals, to improve insulin sensitivity in insulin resistant individuals, to reduce the risk of vascular disease, or as a general nutritional composition.

(21) 545516 (22) 9 Sep 2004

(54) Modified oligonucleotides for telomerase inhibition

(86) PCT/US2004/029718 (87) WO2005/023994

(51) IPC7:A01N43/04

(71) Geron Corporation

(72) Gryaznov, Sergei; Pongracz, Krisztina;

(31) 03 501509 (32) 9 Sep 2003 (33) US

(74) F B RICE & CO, Level 23, 44 Market Street, Sydney, New South Wales 2000, Australia

(57) Provided is a compound comprising the structure: O- (x-L)n, wherein: O is an oligonucleotide comprising at least 10 bases exactly complementary to the human telomerase RNA sequence. x is an optional linker and, if present, is an aminoglycerol linker or a glycerol linker; L is a lipid moiety; and n is an integer from 1-5, wherein if n > 1, each (x-L) component is independently selected. Further provided are similar compounds with specified lipid components and methods of inhibiting telomerase activity in vitro and ex vivo.

(21) 545565 (22) 1 Sep 2004

(54) Formulation of a mixture of Free-B-Ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments

(86) PCT/US2004/028639 (87) WO2005/020932

(51) IPC7:A61K35/78; A61K36/18

(71) Unigen Pharmaceuticals, Inc.

(72) Jia, Qi; Burnett, Bruce; Zhao, Yuan;

(31) 03 499742 (32) 2 Sep 2003 (33) US

(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) Disclosed is the use of a mixture of at least one Free-B-ring flavonoid and at least one flavan for the preparation of a pharmaceutical composition for preventing and treating cyclooxygenase (COX) and lipoxygenase (LOX) mediated diseases, conditions related to neuronal and cognitive function, inhibiting expression of pro-inflammatory cytokines and preventing reactive oxygen species generation and augmenting antioxidant defences in the brain wherein said mixture comprises baicalin isolated from a plant or plants within the Scutellaria genus of plants and catechin, isolated from a plant or plants within the Acacia genus of plants.

Reference has been directed by the Commissioner under section 16 to patent specification 535988.

(21) 545568 (22) 27 Aug 2004

(54) Use of compounds that modulate beta-catenin/TCF activated transcription for manufacture of a medicament to treat cancer

(86) PCT/US2004/028142 (87) WO2005/021025

(51) IPC7:C07D487/04; A61K38/00; C12Q1/02,18,68; G01N33/50; A61K31/4985,5025,53; C07D519/00; C07K14/47; C12N15/09

(71) CHOONGWAE PHARMA CORPORATION

(72) Kahn, Michael; Oh, Se Woong; Kim, Dae Hoon; Ha, Jong Ryul; Hojjati-Emami, Katayoon;

(31) 03 498451 (32) 28 Aug 2003 (33) US


(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) The present disclosure relates to compounds and methods for modulating transcription activated by beta-catenin/TCF, such as the selective inhibition of genes targeted by the Wnt/beta-catenin pathway. In particu-

lar, disclosed is a method for the manufacture of a medicament for the treatment of cancer wherein the method comprises the following steps:

- determining whether or not an agent increases the binding of p300 to beta-catenin and decreases the binding of CPB to beta-catenin;
- selecting an agent which increases the binding of p300 to beta-catenin and decreases the binding of CPB to beta-catenin; and
- combining the agent selected in step b) with one or more pharmaceutically acceptable carriers

wherein the agent is a compound having a structure selected from formula (I).



(21) 545599 (22) 24 Sep 2004

(54) A device that is pushed into the gap between panels in constructing a wall or similar, that then snaps into place to cover the gap

(86) PCT/AU2004/001314 (87) WO2005/031085

(51) IPC7:E04F19/02; E04F13/08; E04C2/00

(71) Coastal Innovations Pty Ltd


(72) Williams, Kevin; Taylor, Alan;

(31) 03 905292 (32) 26 Sep 2003 (33) AU

(31) 03 906894 (32) 11 Dec 2003 (33) AU

(74) F B RICE & CO, Level 23, 44 Market Street, Sydney, New South Wales 2000, Australia

(57) A device (10) for bridging a gap between panels is disclosed. The device comprises a flange (11) that covers the gap between two sheets (52), an extension member (12) that extends from the flange (11) that ends in at least one retaining member (13) that snaps into position on the far faces of the panels (52,) causing the device (10) to be retained against the opposite faces. When inserted into the gap the retaining member(s) (13) are deflected from an initial configuration to a second configuration. After the device (10) is completely inserted the retaining member(s) (13) return to the initial configuration. The flange (11) is also urged into a second configuration from an initial configuration by being held against the outside faces of the panels.



(21) 545618 (22) 31 Mar 2005

(54) Multilayer container trimming

(86) PCT/US2005/010617 (87) WO2005/097465

(51) IPC7:B29C49/74; B65D1/10,16


(71) GRAHAM PACKAGING PET TECHNOLOGIES INC.

(72) Nahill, Thomas E; Piccoli, David P;

(31) 04 816499 (32) 1 Apr 2004 (33) US

(74) PHILLIPS ORMONDE FITZPATRICK, 367 Collins Street, Melbourne, Victoria 3000, Australia

(57) A method of making a plastic container (12) in accordance with one aspect of the present invention includes molding an intermediate container product (24) having a body (12) and a moil (26) integral with the body (12). The body is of layered construction that includes at least one layer of barrier resin that extends part-way into but not throughout the moil (26). The upper portion of the moil (26), in which the barrier material is absent, is removed and can be used for recycling as process regrind. The lower portion of the moil (26) is removed to form the container (12). In the preferred embodiment of the invention, the upper portion of the moil (26) is removed in a laser trimming operation.; The lower portion of the moil (26) is removed in the preferred embodiment of the invention by inserting a plug (not shown) into the open end or mouth of the container, and employing a cutting tool (not shown) that is positioned by the plug (not shown) for accurately trimming of the container product with respect to the mouth of the container (12). The cutting tool preferably is either a pair of shear rollers (not shown) or a laser cutting tool.



(21) 545732 (22) 11 Aug 2004

(54) Crash attenuator with cable and cylinder arrangement for decelerating vehicles

(86) PCT/US2004/025874 (87) WO2005/019680

(51) IPC7:E01F15/00,02,06


(71) SCI Products Inc.

(72) Smith, Jeffrey D; Warner, Randy L; Strong, Kelly R;

(31) 03 638543 (32) 12 Aug 2003 (33) US

(74) CULLEN & CO., Level 32, 239 George Street, Brisbane, QLD 4000, Australia

(57) A vehicle crash attenuator 10 comprising: at least one guiderail; a first structure 12 for bearing vehicle impacts movably mounted on the at least one guiderail; at least one second structure 14 movably mounted on the at least one guiderail behind the first structure 12 and capable of stacking with the first structure 12 upon a vehicle impacting the first structure 12 and causing the first structure 12 to translate into the at least one second structure 14; and a cylinder 44 and a cable 41 running between the cylinder 44 and the first structure 12, the cylinder 44 and cable 41 for applying to the first structure 12 a varying force to resist the first structure 12 translating away when impacted by the vehicle to thereby decelerate the vehicle at or below a predetermined rate of deceleration.




- (21) 545751 (22) 21 Aug 2008
 (54) A water drink with supplements to alleviate the effects of ageing
 (51) IPC7:A23L2/00; A61K9/08; A61K31/616; A61K38/39; A61K31/728
 (71) John Gordon Rutherford
 (72) Rutherford, John Gordon;
 (74) John Gordon Rutherford, 2 Crest Lane, Christchurch 8008, New Zealand
 (57) Disclosed is a water drink including water soluble collagen hydrolysate, hyaluronic acid and antiplatelet activity provided by water soluble aspirin, to mitigate any potential collagen induced platelet aggregation, such as will remain in suspension and interact to present health benefits to alleviate the effects of ageing on skin, joints, and cardiovascular system whereby the recommended daily intake of such nutrients is included in a ready to drink, portable liquid format, such as a bottle or can.

- (21) 545774 (22) 22 Oct 2004
 (54) Process for preparing 7-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
 (86) PCT/KR2004/002705 (87) WO2005/040164
 (51) IPC7:C07D471/04; C07D213/61,74
 (71) LG Life Sciences Ltd
 (72) Shin, Hyun-Ik; Chang, Jay-Hyok; Lee, Kyu-Woong;
 (31) 03 0075962 (32) 29 Oct 2003 (33) KR
 (74) J D Hardie, 14th Floor, 44-48 Emily Place, Auckland, New Zealand
 (57) The present disclosure provides a process for the preparation of highly pure 7-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid (5) in one-pot four steps using a single solvent, wherein ethyl 3-(2,6-dichloro-5-fluoropyridin-3-yl)-3-oxo-propanoate is used as a starting material, which is reacted with dimethyltrimamide dialkylacetate followed by the steps defined in the specification.


- (21) 546033 (22) 23 Aug 2004
 (54) Thermally modified microbial-derived cellulose for in vivo implantation
 (86) PCT/US2004/027354 (87) WO2005/018435
 (51) IPC7:C08B1/00; C12P19/04; D21C1/00; D21C5/00
 (71) Xylos Corporation
 (72) Damien, Christopher James; Oster, Gerry Ann; Beam, Heather Ann;
 (31) 03 497064 (32) 22 Aug 2003 (33) US
 (31) 04 920297 (32) 18 Aug 2004 (33) US
 (74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand
 (57) Disclosed is a method for preparing an implantable or topical material for medical or surgical applications comprising: providing a microbial cellulose; treating said microbial cellulose to render said cellulose non-pyrogenic; partially dehydrating said microbial cellulose by exposure to temperatures below 0°C, then subsequently exposing said microbial cellulose to temperatures above 0°C; and subsequently discarding liquid that was removed.

- (21) 546159 (22) 24 Sep 2004
 (54) Carbamoyl-type benzofuran derivatives
 (86) PCT/JP2004/013891 (87) WO2005/030759
 (51) IPC7:C07D405/12,14; C07D407/14; A61K31/4545,4439,4433,443; A61P7/02
 (71) Mitsubishi Tanabe Pharma Corporation

- (72) Kawaguchi, Takayuki; Akatsuka, Hidenori; Morimoto, Masamichi; Watanabe, Tatsuya; Iijima, Toru; Murakami, Jun;
 (31) 03 334597 (32) 26 Sep 2003 (33) JP
 (74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand
 (57) Disclosed is a compound of formula [1], with substituents as defined in the specification, which is useful as an inhibitor of activated blood coagulation factor X (FXa) for treating thrombosis.



- (21) 546177 (22) 18 Aug 2004
 (54) Menthol propyleneglycol-carbonate and analogs thereof as insect pest repellents
 (86) PCT/US2004/026900 (87) WO2005/025313
 (51) IPC7:A01N37/00; C07C13/18
 (71) POSEIDON OCEAN SCIENCES
 (72) Matias, Jonathan R;
 (31) 03 500392 (32) 5 Sep 2003 (33) US
 (74) PIPERS, Level 1, 5A Pacific Rise, Mt Wellington, Auckland, New Zealand
 (57) Disclosed is a method for repelling insects from a site which comprises applying to said site an insect repelling amount of a compound of formula (I) wherein:
 R represents a straight or branched chain, substituted or unsubstituted lower alkyl radical, or a straight or branched chain, substituted or unsubstituted lower alkenyl radical;
 X represents a carbonyl linking group (-C(=O)-) or a valence bond;
 n is 0 or 1; and
 R' represents a radical selected from the group consisting of substituted or unsubstituted hydroxyalkoxy and substituted or unsubstituted hydroxyalkyl, when n is 1; and R' represents an alkylamine radical when n is 0.
 Also disclosed is an insect repellent, cosmetic or personal care composition, a household cleaning composition, a coating composition or a fabric comprising the above compound of formula (I).



- (21) 546221 (22) 12 Oct 2004
 (54) Method and apparatus providing performance improvement for GPRS neighbour cell measurement reporting when packet broadcast control channel is not available
 (86) PCT/IB2004/003321 (87) WO2005/039205
 (51) IPC7:H04Q7/20

(71) Nokia Corporation

(72) Laitinen, Pasi; Huusko, Hannu; Kangas, Antti O;

(31) 03 687011 (32) 16 Oct 2003 (33) US

(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) An apparatus (mobile station 100) operable with a network (20) in a general packet radio service mode of operation comprises a radio frequency transceiver; and a controller that operates in at least one network control mode of operation to determine if a cell (30) to which the apparatus is currently assigned has a packet broadcast control channel and, if the cell does have the packet broadcast control channel, operates further to send a packet measurement report message to a network for reporting on neighbour cells identified in a global system for mobile neighbour cell list received from the packet broadcast control channel.

The controller is responsive to a condition where the cell does not have the packet broadcast control channel to determine if the global system for mobile neighbour cell list has been received through the transceiver from a broadcast control channel and, if it has, to send a packet measurement report message to the network for reporting on neighbour cells identified in the global system for mobile neighbour cell list received from the broadcast control channel, while indicating the list that was used either implicitly or explicitly or if the global system for mobile neighbour cell list has not been received, the controller sends a packet measurement report message to the network for reporting on neighbour cells identified in a general packet radio service broadcast control channel allocation received from the broadcast control channel, while indicating the list that was used either implicitly or explicitly.




FIG. 1

(21) 546260 (22) 8 Nov 2004

(54) Process for producing radioactive-fluorine-labeled compound

(86) PCT/JP2004/016533 (87) WO2005/044758

(51) IPC7:C07B59/00; C07H5/02; C07H13/06; G21H5/02

(71) NIHON MEDI-PHYSICS CO., LTD.

(72) Hirano, Keiichi;

(31) 03 381032 (32) 11 Nov 2003 (33) JP

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) An on-column process by which various radioactive-fluorine-labeled compounds can be obtained in a high yield is disclosed, wherein the process comprises a step in which $[^{18}\text{O}]$ water containing $[^{18}\text{F}]$ fluoride ions is introduced into a column packed with an anion-exchange resin for labeled-compound synthesis to collect the $[^{18}\text{F}]$ fluoride ions, a step in which the column is dehydrated, and a step in which a substrate is

introduced into the column to cause a displacement reaction between the $[^{18}\text{F}]$ fluoride ions collected in the column and a leaving group of the substrate to thereby obtain a radioactive-fluorine-labeled compound, wherein the step of passing carbon dioxide through the column is conducted between the column dehydration step and the substrate introduction step.

(21) 546262 (22) 1 Sep 2004

(54) Manually operated apparatus, and balloon unit and valve housing for a manually operated respiration apparatus

(86) PCT/NL2004/000606 (87) WO2005/021074

(51) IPC7:A61M16/00,20


(71) EMERGENCY PULMONARY CARE B.V.

(72) Lugtigheid, Gerardus Wilhelmus;

(31) 03 1024206 (32) 1 Sep 2003 (33) NL

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) A manually operated respiration apparatus 1, comprising a respiration housing 2, provided with a respiration channel 4 for connection with a patient to whom artificial respiration is to be applied, which respiration channel 4 is connected via a valve system with an inflow port connected to a balloon unit 3 for supplying air to the patient via the respiration channel 4 and with one or more outflow ports for evacuating air exhaled by the patient into the respiration channel 4 to the environment, wherein the balloon unit 3 comprises a resilient bellows 10 provided with an inlet opening 8 and an outlet opening 9, wherein, further, in the inlet opening 8 of the bellows 10, a non-return valve 11 is included and wherein the outlet opening 9 of the bellows 10 is connected with the inflow port of the respiration housing 2, characterized in that the balloon unit 3 is provided with a valve housing accommodating an overpressure protection for evacuating air from the bellows 10 when a predetermined pressure value is exceeded.



(21) 546264 (22) 1 Oct 2004

(54) Implantable penile prosthesis pump

(86) PCT/US2004/032605 (87) WO2005/034815


(51) IPC7:A61F2/26; F04B43/00

(71) AMS Research Corporation

(72) Kuyava, Charles C;

(31) 03 508123 (32) 2 Oct 2003 (33) US
(74) SPRUSON & FERGUSON, GPO Box 3898, Sydney, NSW, 2001, Australia

(57) A penile prosthesis (100) is provided, which includes at least one cylinder (112, 114), a reservoir (118), and a pump (116) including a pump housing, at least one reservoir channel (124) fluidly coupling the pump housing to the reservoir, at least one cylinder tube (120, 122) fluidly connecting the pump housing to the cylinders, a fluid passageway fluidly coupled to the reservoir channel and a transfer chamber, wherein the transfer chamber is fluidly coupled to the at least one cylinder tube, and a bypass chamber comprising bypass input and output channels and a bypass check-valve biased towards a closed position. The pump also includes a pump bulb fluidly connected to the fluid passageway between the bypass input channel and the bypass output channel along the length of the fluid passageway. Also disclosed is a pump for transferring fluid between a reservoir and at least one cylinder within a penile prosthesis.




(21) 546287 (22) 3 Sep 2004
(54) Human epo mimetic hinge core mimetibodies, compositions, methods and uses
(86) PCT/US2004/028976 (87) WO2005/032460
(51) IPC7:C07K14/00; C07K16/46; A61K37/00; A61K38/00; A61K39/00; C12N15/00; C12N5/00
(71) CENTOCOR, INC.
(72) Heavner, George; Knight, David M; Scallon, Bernard; Ghayeb, John; Nesspor, Thomas C; Huang, Chichi;
(31) 03 507349 (32) 30 Sep 2003 (33) US
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand
(57) Disclosed are specific human EPO mimetic hinge core mimetibodies, including isolated nucleic acids that encode at least one EPO mimetic hinge core mimetibodies. Further disclosed are vectors, host cells, transgenic animals or plants, methods of making and using thereof, and therapeutic compositions and methods.

(21) 546293 (22) 28 Sep 2004
(54) Toilets with quick flush trapways
(86) PCT/US2004/031575 (87) WO2005/033423
(51) IPC7:E03D11/00,18
(71) KOHLER CO.
(72) Kuru, William C; Krishnamurty, Venkata S; Halloran, Daniel N; Liu, Patrick Ying-Te; Mukerji, Sudip;
(31) 03 678362 (32) 3 Oct 2003 (33) US
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is a toilet of the type having a trapway, the trapway extending between a bowl opening and an outlet, the trapway having a curved water dam region and an up-leg extending from the bowl opening to above the bowl opening to a down-leg, wherein:

the down-leg slopes in essentially uniform cross-section in a rearward direction from the water dam region to an essentially horizontal baffle extending forward from a rear wall of the down-leg adjacent a lower portion of the down-leg, the lower portion of the down-leg being linked to an out-leg communicating with the outlet.



(21) 546315 (22) 5 Oct 2004
(54) Oligopeptides as coating material for medical products
(86) PCT/EP2004/011117 (87) WO2005/039629
(51) IPC7:A61K38/55,34; A61K31/198; A61L31/10,14; A61P41/00; A61L31/16
(71) Hemoteq AG
(72) Hoffman, Erika; Hoffman, Michael; Horres, Roland;
(31) 03 680035 (32) 7 Oct 2003 (33) US
(74) JAMES & WELLS, Level 11, PricewaterhouseCoopers Centre, 119 Armagh Street, Christchurch, New Zealand
(57) Disclosed is a medical product coated with a pharmaceutical composition including a compound of the formula R-Lys-X and at least one pharmaceutically acceptable carrier, polymer matrix, solvent and/or diluents, wherein X represents a hydroxyl group, an amino group, a monoalkyl or dialkylamino group, an alkoxy group, Pro, Pro-Thr, Pro-Val, Pro-Ala, Pro-Arg, Pro-Asn, Pro-Asp, Pro-Cys, Pro-Glu, Pro-Gln, Pro-Gly, Pro-His, Pro-Ile, Pro-Leu, Pro-Lys, Pro-Met, Pro-Phe, Pro-Pro, Pro-Ser, Pro-Trp, Pro-Thr-Thr, Pro-Thr-Val, Pro-Thr-Ala, Pro-Thr-Arg, Pro-Thr-Asn, Pro-Thr-Asp, Pro-Thr-Cys, Pro-Thr-Glu, Pro-Thr-Gln, Pro-Thr-Gly, Pro-Thr-His, Pro-Thr-Ile, Pro-Thr-Leu, Pro-Thr-Lys, Pro-Thr-Met, Pro-Thr-Phe, Pro-Thr-Pro, Pro-Thr-Ser, Pro-Thr-Trp, Pro-Val-Thr, Pro-Val-Val, Pro-Val-Ala, Pro-Val-Arg, Pro-Val-Asn, Pro-Val-Asp, Pro-Val-Cys, Pro-Val-Glu, Pro-Val-Gln, Pro-Val-Gly, Pro-Val-His, Pro-Val-Ile, Pro-Val-Leu, Pro-Val-Lys, Pro-Val-Met, Pro-Val-Phe, Pro-Val-Pro, Pro-Val-Ser, Pro-Val-Trp and wherein R is selected from the group consisting of hydrogen, acyl group, acetyl group, an amino acid or a peptide with 2 - 70 amino acids.

(21) 546346 (22) 29 Sep 2004
(54) Methods for enhancing stress tolerance in plants and compositions thereof
(86) PCT/US2004/031856 (87) WO2005/033318
(51) IPC7:C12N15/82; C07K14/195; A01H5/00
(71) MONSANTO TECHNOLOGY LLC
(72) Fernandes, Mary;
(31) 03 506717 (32) 29 Sep 2003 (33) US
(31) 03 530453 (32) 17 Dec 2003 (33) US
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Provided is a plant or a seed thereof having inserted into the genome of its cells a recombinant DNA encoding a protein comprising a cold shock domain, including bacterial cold shock proteins, wherein expression of said protein confers drought-tolerance on said plant. Further provided are methods of manufacturing such transgenic plants and introgressing said recombinant DNA to second plants and screening abiotic stress tolerant plants.

(21) 546499 (22) 27 Oct 2004

(54) Optical fibre splice connector using clamping connectors

(86) PCT/GB2004/004519 (87) WO2005/052665

(51) IPC7:G02B6/38,25


(71) TYCO ELECTRONICS RAYCHEM NV

(72) Watte, Jan; Van Noten, Lodewijk; Elenbaas, Jacob Arie; De Boer, Thomas; Rietveld, Willy;

(31) 03 0325697 (32) 4 Nov 2003 (33) GB

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) An optical fibre connector 1 for forming a mechanical splice between first and second bare optical fibres 21 stripped of coatings, the connector 1 comprising a connector body that is divided into at least two parts 3 5 along at least part of a length thereof, arranged such that the optical fibres 21 may be clamped between the parts and that comprises at least two main clamping sections dimensioned to clamp directly onto the bare fibre of the first and second optical fibres 21, wherein the connector body includes at least one additional clamping section dimensioned to clamp onto a coated portion of one of the optical fibres 21, and the clamping sections are arranged such that the first optical fibre 21 may be clamped by a first of the main clamping sections independently of the second optical fibre, enabling the clamping of the first fibre 21 against rotational and axial movement with respect to the connector body to remain substantially undisturbed by subsequent clamping or unclamping of the second fibre 21.



(21) 546580 (22) 2 Nov 2004

(54) High throughput functional assay for G-protein coupled receptors using a rap-ras chimeric protein

(86) PCT/US2004/036595 (87) WO2005/042574

(51) IPC7:C07K14/47; G01N33/50; C12N15/10; C12Q1/68

(71) ACADIA PHARMACEUTICALS INC.

(72) Burstein, Ethan S; Piu, Fabrice; Ma, Jian-Nong; Weissman, Jacques Thomas; Weiner, David M; Nash, Norman; Spalding, Tracy; Currier, Erika; Scully, Audra L;

(31) 03 517143 (32) 3 Nov 2003 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is a method of determining whether a substance is a ligand for a G-protein coupled receptor (GPCR), comprising:

(a) providing a cell culture which comprises cells comprising a first nucleic acid which encodes a GPCR which increases or decreases cellular proliferation through a GPCR cascade in response to a ligand, a second recombinant nucleic acid which encodes a marker indicative of the extent of cellular proliferation, and a third recombinant nucleic acid encod-

ing a Ras effector domain and a Rap input domain operably coupled to said Ras effector domain;

(b) contacting said cell culture with a test compound; and

(c) determining the level of cellular proliferation

(21) 546668 (22) 4 Oct 2004

(54) Hypo- and hyper-acetylated meningococcal capsular saccharides

(86) PCT/IB2004/003366 (87) WO2005/033148

(51) IPC7:A61K31/715; A61K39/095; C08B37/00

(71) Novartis Vaccines and Diagnostics S.r.l.

(72) Costantino, Paolo;

(31) 03 0323103 (32) 2 Oct 2003 (33) GB

(74) F B RICE & CO, Level 23, 44 Market Street, Sydney, New South Wales 2000, Australia

(57) Disclosed is a modified serogroup W135 meningococcal capsular saccharide conjugated to a carrier protein, wherein: (a) < 29% of the sialic acid residues in the saccharide are O-acetylated at the 7 position; and/or (b) > 26% of the sialic acid residues in the saccharide are O-acetylated at the 9 position. Also disclosed a modified meningococcal capsular saccharide, wherein the saccharide comprises n or more repeating units of the disaccharide unit:

[sialic acid] - [hexose]

where the hexose is either galactose or glucose and n is an integer from 1 to 100, and wherein:

(a) < x% of the sialic acid residues in said n or more repeating units are O-acetylated at the 7 position; and/or

(b) when hexose is galactose, > y% of the sialic acid residues in said n or more repeating units are O-acetylated at the 9 position, and when hexose is glucose, > y% or < z% of the sialic acid residues in said n or more repeating units are O-acetylated at the 9 position, where: when hexose is galactose, x is 29 and y is 26; and when hexose is glucose, x is 9, y is 29 and z is 27.

(21) 546784 (22) 8 Oct 2004

(54) Linking transconnector for coupling spinal rods

(86) PCT/US2004/033369 (87) WO2005/034779

(51) IPC7:A61B17/56


(71) SYNTHES GMBH

(72) Ryan, Christopher J; Keyer, Thomas R; Walther, Martin;

(31) 03 681351 (32) 9 Oct 2003 (33) US

(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand

(57) A linking transconnector (10) is disclosed for coupling a first longitudinal spinal rod to a second longitudinal spinal rod. The linking transconnector generally includes a pair of hook engaging members (50) for engaging the longitudinal spinal rods, a lateral rod (20) for spanning a distance between the hook engaging members, and a locking element (100) which interconnects the hook engaging members with the rod. The locking element is configured to allow for multiple degrees of adjustment to permit the linking transconnector to accommodate for varying spinal rod alignments. The locking elements also permits the location of the lateral rod to be fixed relative to the hook engaging members once the desired position of the lateral rod with respect to the longitudinal spinal rods has been achieved. The locking element may also be able to fix the position of the lateral rod with respect to the hook engaging members by a force applied to the locking element.



(21) 546787 (22) 29 Oct 2004

(54) Pyridine compounds as inhibitors of dipeptidyl peptidase IV

(86) PCT/JP2004/016457 (87) WO2005/042488

(51) IPC7:C07D213/12,55,56,59,71,75,80,82; C07D401/06,12; C07D405/12; C07D409/12; C07D413/06,12; C07F9/40; A61P3/00

(71) Takeda Pharmaceutical Company Limited

(72) Oi, Satoru; Maezaki, Hironobu; Suzuki, Nobuhiro;


(31) 04 030491 (32) 6 Feb 2004 (33) JP

(31) 04 165977 (32) 3 Jun 2004 (33) JP

(31) 03 373776 (32) 31 Oct 2003 (33) JP

(74) BALDWIN'S INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) Disclosed is a compound represented by the formula I wherein R¹ and R² are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted hydroxy group; R³ is an optionally substituted aromatic group; R⁴ is an amino group; L is a C1-10 alkylene group; Q is a bond or a divalent chain hydrocarbon group; wherein the rest of the substituents are disclosed within the specification or a salt thereof. Also disclosed is a peptidase inhibitor comprising a compound of any one of claims 1-8 or a salt thereof or a prodrug thereof.



(21) 546794 (22) 14 Oct 2004

(54) Cable with offset filler

(86) PCT/US2004/034073 (87) WO2005/045855

(51) IPC7:H01B11/06

(71) ADC INCORPORATED


(72) Kenny, Robert; Reeves, Stuart; Ford, Keith; Grosh, John W; Stutzman, Spring; Wiekhorst, David; Johnston, Fred;

(31) 03 516007 (32) 31 Oct 2003 (33) US

(31) 03 746800 (32) 26 Dec 2003 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) A cable comprising at least two pairs of twisted conductors (more specifically, relating to twisted pair communication cables for high-speed data communications applications) is disclosed. The cable includes at least two twisted pairs of insulated conductors, a non-conductive filler, which includes a base portion and at least one extension, the base portion including a plurality of legs, at least one leg having a length approximately equal to the diameter of one of the twisted pairs of conductors, the plurality of legs defining pockets with the twisted pairs of conductors being positioned within the pockets, the extension(s) extending radially outwards from the leg(s), and a jacket that surrounds the twisted pairs of conductors and the filler, the extension of the filler creating a ridge on the exterior of the jacket that extends along the length of the cable. The filler may be helically twisted over a certain distance. The cables are configured to efficiently and accurately propagate high-speed data signals by, among other functions, limiting at least a subset of the following: impedance deviations, signal attenuation, and alien crosstalk along the predefined distance.



(21) 546853 (22) 27 Apr 2006 (23) 27 Apr 2007

(54) Content management system

(51) IPC7:G06F17/30,60; G06F3/02,12; G06F13/00; G06F17/24

(71) EBIZDOCZ LIMITED

(72) Jorgensen, Christine Dawn; Monkton, Bruce; Johnson, Christopher Michael;

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) A system for providing documents to users in organisations is disclosed. Each organisation is operating in at least one industry and is obliged or desires to comply with one or more requirements in relation to activities carried out in relation to that organisation. For each organisation the requirements that the organisation is obliged or desires to comply with are requirements that are specified for: the organisation itself, the industry that the organisation operates in, and/or a range of industries, one of which is the industry in which the organisation operates in. The system comprises

input means for receiving, from one of the organisations, a request for a document relating to an activity to be undertaken by a user in relation to that organisation,

computer system for generating a document relating to that activity with the document comprising content influenced by at least one requirement the organisation is obliged or desires to comply with in relation to carrying out that activity, and

a data store with a plurality of templates, at least some of which are common templates used for generating documents for a plurality of the organisations. The computer system generates the document from at least one of the plurality of templates and if the request for a document relates to an activity that is carried out by a plurality of the organisations and that is governed by requirements specified for an industry or range of industries, then the template used for generating the document is one of the common templates. The common template used is a template also used for generating documents in response to requests received for documents from any of the plurality of the organisations, such documents

relating to that activity to be undertaken by a user in relation to any of the plurality of the organisations, and such templates comprising content influenced by at least one requirement that plurality of the organisations are obliged or desire to comply with, each requirement being a requirement specified for: an industry that the plurality of the organisations operate in, and/or a range of industries, one of which is the industry in which the plurality of the organisations operate in.

The system also has an output system for providing the document to the user. Each common template is updateable to change the content, such that if any change occurs in the at least one requirement specified for the plurality of the organisations, any common templates relevant to those plurality of the organisations can be changed so that a document generated from the template will include content influenced by the changed requirements.

Divisional filed as 572333

(21) 546903 (22) 13 Oct 2004

(54) Method and kit for primer based amplification of nucleic acids

(86) PCT/US2004/033818 (87) WO2005/038039

(51) IPC7:C12Q1/68

(71) GENACO BIOMEDICAL PRODUCTS, INC.

(72) Han, Jian;

(31) 03 510762 (32) 13 Oct 2003 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is a method for diagnosis or differential diagnosis of disease agents and secondary disease agents. The method disclosed uses a amplification strategy to allow sensitive and specific amplification of target sequences from any disease agents and/or secondary disease agent whose nucleic acid sequence is known. The method utilizes at least one set of target enrichment primers specific for the disease agent or secondary disease agent to be detected (present at a low concentration) and at least one pair of shared target amplification primers (present at high concentrations). At least one pair of said target enrichment primers comprises a binding sequence for the target amplification primers. Therefore, the use of the method allows multiplex amplification reactions to be carried out without the need for empirical optimization of the multiplex amplification parameters.

(21) 547225 (22) 12 Nov 2004

(54) Particle-forming compositions containing fused pyrrolocarbazoles

(86) PCT/US2004/037928 (87) WO2005/051958

(51) IPC7:A61K31/55; C07D498/22

(71) CEPHALON, INC.


(72) Dickason, Dave; McIntyre, Bradley T; Patel, Piyush R;

(31) 03 718077 (32) 20 Nov 2003 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Provided is a composition comprising a fused pyrrolocarbazole of the depicted formula, wherein R3 and R4 are selected from H, alkyl, Cl, Br, CH2OH, CH2SOCH2CH3, CH2SO2CH2CH3, NHCONHC6H5, CH2SCH2CH3, CH2SC6H5, NHCO2CH3, CH2OC(=O) NHCH2CH3, N(CH3)2, CH=NNH, CH2N(CH3)2 and CH2OCH2CH3, R7 is selected from H and alkyl; and R15 and R16 are independently selected from H, alkyl, OH, CH2OH, alkoxy, and C(=O)Oalkyl; or a stereoisomer or pharmaceutically acceptable salt form thereof; at least 20% (w/w) of a polyoxylstearate; and at least one polyethylene glycol.

Divisional filed as 577384



(21) 547518 (22) 22 Dec 2004

(54) Crystal of salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)amino-phenoxy)-7-methoxy-6-quinolinecarboxamide or of solvate thereof and processes for producing these

(86) PCT/JP2004/019223 (87) WO2005/063713

(51) IPC7:C07D215/48

(71) EISAI R&D MANAGEMENT CO., LTD.

(72) Matsushima, Tomohiro; Nakamura, Taiju; Yoshizawa, Kazuhiro; Kamada, Atsushi; Ayata, Yusuke; Suzuki, Naoko; Arimoto, Itaru; Sakaguchi, Takahisa; Gotoda, Masaharu;

(31) 03 430939 (32) 25 Dec 2003 (33) JP

(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) Provided is a crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, wherein said crystalline compound is the hydrochloride of said compound, the hydrobromide of said compound, the p-toluenesulfonate of said compound, the sulfate of said compound, the methanesulfonate of said compound or the ethanesulfonate of said compound, or the solvate of said salt. Further provided are processes for preparing the compounds, anti-tumor agents comprising the compounds and use of the compounds in the manufacture of prophylactic or therapeutic agents for a disease in which angiogenesis inhibition is effective.

(21) 547558 (22) 16 Nov 2004

(54) Compositions and methods for the treatment of tumor of hematopoietic origin

(86) PCT/US2004/038262 (87) WO2005/049075

(51) IPC7:A61K39/00; C07K14/705; C07K16/30

(71) GENENTECH, INC.

(72) Crowley, Craig; Desauvage, Frederic J; Eaton, Dan L; Ebens, Allen; Polson, Andrew; Smith, Victoria;

(31) 03 520842 (32) 17 Nov 2003 (33) US

(31) 03 532426 (32) 24 Dec 2003 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Provided is the use of an antibody that specifically binds a protein having at least 80% amino acid sequence identity to a specified polypeptide sequence or a corresponding nucleotide sequence in the manufacture of a medicament for inhibiting unwanted cell growth or treating cancer wherein the medicament is formulated for contacting said cell with an antibody that binds to said protein thereby causing an inhibition of growth of said cell, wherein said antibody is conjugated to a growth inhibitory agent or cytotoxic agent.

Divisional filed as 576411

(21) 547586 (22) 24 Nov 2004

(54) Built-in light

(86) PCT/EP2004/013335 (87) WO2005/066537

(51) IPC7:F21S8/02; F21V11/14; F21V14/02,04; F21V21/30; F21V3/00; F21V7/00


(71) HARTMUT S ENGEL

(72) Engel, Hartmut S;

(31) 03 0360947 (32) 23 Dec 2003 (33) DE

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) A built-in lamp comprising a holder for fastening in an installation surface a bulb 6 and a reflector 4, with a reflector 4 opening disposed in the direction of illumination defining a direct light discharge region 1, which is surrounded by a diffuse light discharge region 1 such that scattered light is discharged from the diffuse light discharge region 1 around the direct light discharge region 1, wherein the bulb 6 and the direct light reflector 4 are arranged in a housing 10 whose inner surface is made at least regionally as an additional reflector 7; and in that the housing 10 is terminated in at least a largely dust-proof manner by a translucent scattering plate 8 in the region of the diffuse light discharge region 1 and by a plate 13 in the region of the direct light discharge region 1.



- (21) 547619 (22) 26 Oct 2004
 (54) Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin
 (86) PCT/US2004/035430 (87) WO2005/051234
 (51) IPC7:A61K9/00
 (71) pSivida Inc
 (72) Chou, Kang-Jye; Guo, Hong; Ashton, Paul; Shimizu, Robert W; Watson, David A;
 (31) 03 714549 (32) 13 Nov 2003 (33) US
 (31) 04 543368 (32) 9 Feb 2004 (33) US
 (74) Shelston IP, Level 21, 60 Margaret Street, Sydney, NSW 2000, Australia
 (57) Provided is a drug delivery device shaped and sized for injection in a needle or cannula ranging in size from 30 gauge to 15 gauge, comprising: a core including one or more drugs; and a polymeric skin at least partially, but not completely surrounding the core, the skin comprising a first one or more polymers, impermeable to the passage of drug; wherein the device provides sustained release of the one or more drugs when exposed to a biological medium. Further provided are devices with specified polymers and drugs.

Divisional filed as 575950


- (21) 547839 (22) 6 Apr 2004
 (54) Polymer composite gloves having fibrous coating on dipped rubber
 (86) PCT/US2004/010499 (87) WO2005/068186
 (51) IPC7:B32B25/02,08
 (71) Ansell Healthcare Products LLC
 (72) Lucas, David Marc; Mustafa, Nuzaimah Binti; Hassan, Noorman Bin Abu;
 (31) 03 741413 (32) 19 Dec 2003 (33) US
 (74) Shelston IP, Level 21, 60 Margaret Street, Sydney, NSW 2000, Australia
 (57) Disclosed is an elastomeric article comprising:
 a first layer, the first layer comprising a natural or synthetic polymer; and
 a second layer bonded to the first layer comprising a polymer composite fibrous coating, the polymer composite fibrous coating comprising at least one elastomer, a flock of fibers and a micronised wax.

- (21) 547905 (22) 2 Dec 2004
 (54) A medical product comprising tiotropium in a moisture-proof container
 (86) PCT/SE2004/001790 (87) WO2005/053644
 (51) IPC7:A61K31/4745
 (71) BOEHRINGER INGELHEIM INTERNATIONAL GMBH
 (72) Nilsson, Thomas; Myrman, Mattias; Niemi, Alf; Calander, Sven;
 (31) 03 0303269 (32) 3 Dec 2003 (33) SE
 (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand
 (57) Disclosed is a dose of tiotropium, in a container with an aluminium high barrier seal to prevent moisture reaching the powder, suitable for use in a dry powder inhaler.

- (21) 547920 (22) 23 Dec 2004
 (54) Definitive endoderm
 (86) PCT/US2004/043696 (87) WO2005/063971
 (51) IPC7:C12N5/08
 (71) CyThera, Inc
 (72) D'Amore, Kevin Allen; Agulnick, Alan D; Baetge, Emmanuel E;
 (31) 03 532004 (32) 23 Dec 2003 (33) US
 (31) 04 586566 (32) 9 Jul 2004 (33) US
 (31) 04 587942 (32) 14 Jul 2004 (33) US
 (74) Freehills Patent & Trade Mark Attorneys, Level 43, 101 Collins Street, Melbourne, Victoria 3000, Australia
 (57) Disclosed is an in vitro cell culture comprising human cells wherein at least 15% of said human cells are definitive endoderm cells, said definitive endoderm cells being multipotent cells that can differentiate into cells of the gut tube or organs derived therefrom.

- (21) 547987 (22) 20 Dec 2004
 (54) Yeast strains with improved fructose fermentation capacity
 (86) PCT/EP2004/014577 (87) WO2005/058947
 (51) IPC7:C07K14/395
 (71) DSM IP Assets B.V.; INSITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE
 (72) Pellerine, Patric Jacques Marie; Blondin, Bruno; Sablayrolles, Jean-Marie; Guillaume, Carole;
 (31) 03 03078992 (32) 19 Dec 2003 (33) EP
 (74) PHILLIPS ORMONDE FITZPATRICK, 367 Collins Street, Melbourne, Victoria 3000, Australia
 (57) Provided is an isolated HXT3 hexose transporter having an improved capacity to transport fructose with respect to the capacity to transport fructose of a specified sequence of wild type hexose transporter and wherein said isolated HXT3 hexose transporter has an amino acid sequence having at least a mutation at position Ile209. Further provided is a similar transporter additionally comprising at least a mutation at a position selected from the group consisting of Met 324, Leu 388, Tyr 389, Ile 392, Glu 414, Gly 415, Ile 449, Leu 471. Also provided are yeast cells containing the transporter and use of the yeast for fermentation of carbohydrates.

- (21) 548068 (22) 26 Nov 2004
 (54) Neck brace for motor sports which diverts impact loads away from the neck
 (86) PCT/ZA2004/000148 (87) WO2005/051251
 (51) IPC7:A61F5/055; A63K3/00
 (71) XCEED HOLDINGS (PTY) LIMITED
 (72) Leatt, Christopher James;
 (31) 03 9174 (32) 26 Nov 2003 (33) ZA
 (74) PIPERS, Level 1, 5A Pacific Rise, Mt Wellington, Auckland, New Zealand
 (57) A neck brace (10) is disclosed. The brace comprises two sections (12, 14) which are releasably connected to one another along a line (18) that splits a ring (42) which in use encircles the wearer's neck. The ring (42) has upwardly facing surfaces (30, 76, 20) which limit tilting movement of a helmeted head in all directions. The brace also has a column (62) which extends downwardly from the ring (42) for transferring loads to the wearer's back on each side of the spine and a forward facing lower lip (22) that transfers loads to the wearer's upper chest.



(21) 548082 (22) 23 Jun 2006 (23) 25 Jun 2007

(54) Dermal pesticide containing vitamin D3

(51) IPC7:A01M7/00; A01N25/30,02; A01N27/00

(60) 548082

(71) Warren Roy Agnew

(72) Agnew, Warren Roy; Razzak, Majid Hameed Abdul;

(74) PIPERS, Level 1, 5A Pacific Rise, Mt Wellington, Auckland, New Zealand

(57) Disclosed is a method of killing a non-human animal pest comprising topically administering to the animal pest a topical pesticide formulation comprising an effective amount of cholecalciferol or 25-hydroxycholecalciferol and at least one carrier which is capable of delivering the cholecalciferol or 25-hydroxycholecalciferol transdermally to cause the death of an animal pest.

Also disclosed is an apparatus for delivering a topical pesticide formulation to an animal pest, said apparatus comprising means forming at least one partially enclosed space into which the animal can enter or pass through, and at least one automatic dispensing apparatus having a spray means, and a container containing a formulation comprising an effective amount of cholecalciferol or 25-hydroxycholecalciferol and at least one carrier which is capable of delivering the cholecalciferol or 25-hydroxycholecalciferol transdermally to the animal, said automatic dispensing apparatus being operatively connected to the enclosed space, said enclosed space including at least one sensing means therein to detect when an animal is present in or near the space, wherein said sensing means activates the automatic dispensing apparatus to deliver a predetermined quantity of the cholecalciferol or 25-hydroxycholecalciferol formulation topically to the animal.

(21) 548096 (22) 21 Dec 2004

(54) Compositions and methods for the treatment of tumor of hematopoietic origin

(86) PCT/US2004/043514 (87) WO2005/063299

(51) IPC7:A61K39/00; A61K47/48; C07K14/705

(71) GENENTECH, INC

(72) Chang, Wesley; De Sauvage, Frederic; Eaton, Dan L; Ebens, Allen J; Frantz, Gretchen; Hongo, Jo-Anne; Koeppen, Hartmut; Polson, Andrew; Smith, Victoria;

(31) 03 532426 (32) 24 Dec 2003 (33) US

(31) 04 038262 (32) 16 Nov 2004 (33) US

(31) 04 989826 (32) 16 Nov 2004 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is the use of an antibody, oligopeptide or organic molecule that binds to a protein having at least 80% amino acid sequence identity to: (a) the polypeptide having the amino acid sequence shown in Figure 10 (SEQ ID NO: 6); (b) the polypeptide having the amino acid sequence shown in figure 10 (SEQ ID NO: 6), lacking its associated signal peptide; (c) a polypeptide encoded by the nucleotide sequence shown in Figure 5 (SEQ ID NO: 5), or (d) a polypeptide encoded by the full-length coding region of the nucleotide sequence shown in Figure 5 (SEQ ID NO: 5) for the preparation of a medicament for inhibiting the growth of a cell that expresses said protein, wherein the antibody for the polypeptide having

the amino acid sequence shown in Figure 6 (SEQ ID NO: 6) is produced by a hybridoma 7D11.1.1 (ATCC Accession Number PTA-6340).

Divisional filed as 576191

(21) 548151 (22) 16 Dec 2004

(54) Absorbent structure and absorbent article comprising the absorbent structure

(86) PCT/SE2004/001886 (87) WO2005/063312

(51) IPC7:A61F13/53; A61L15/60


(71) SCA HYGIENE PRODUCTS AB

(72) Osterdahl, Eje; Hanson, Charlotta; Karlsson, Karl;

(31) 03 0303558 (32) 30 Dec 2003 (33) SE

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) An absorbent structure (103) for use in a diaper (100), an incontinence pad, a sanitary towel is disclosed. The absorbent structure has at least one absorbent layer (112) comprising fluff pulp and superabsorbent particles. The average absorption capacity per superabsorbent particle in the absorbent layer is greater than 8.0 mg sodium chloride solution, and the number of superabsorbent particles per cm³ of the absorbent layer is smaller than 1100.



(21) 548177 (22) 1 Dec 2004

(54) A biomimetic composition reinforced by a polyelectrolytic complex of hyaluronic acid and chitosan

(86) PCT/US2004/040051 (87) WO2005/054440

(51) IPC7:A61K45/00; C12N11/02; C12N5/00,08

(71) Tissue Engineering Consultants Inc

(72) Brekke, John H;

(31) 03 525965 (32) 1 Dec 2003 (33) US

(31) 04 999848 (32) 30 Nov 2004 (33) US


(74) Pizzzeys Patent and Trade Mark Attorneys, Level 2, Woden Plaza Offices, Woden Town Square, Woden, ACT 2606, Australia

(57) Provided is a fluid mass composition formed by the process comprising: blending dry hyaluronic acid particles and dry protonated chitosan particles; and adding an aqueous solution to the blend, wherein said fluid mass composition comprises unreacted protonated chitosan hydrogel, unreacted hyaluronic acid viscoelastic gel and polyelectrolytic complex fibers, wherein said polyelectrolytic complex fibers form a three dimensional network throughout the fluid mass composition that surrounds and penetrates the unreacted protonated chitosan hydrogel and the unreacted hyaluronic acid viscoelastic gel and maintains homogeneous regions of the unreacted protonated chitosan hydrogel and the unreacted hyaluronic acid viscoelastic gel. Further provided are tissue engineering materials and biomimetic compositions comprising the said fluid mass composition.

(21) 548186 (22) 20 Sep 2004

(54) Apparatus for temperature modification utilising a heat-exchange device consisting of flexible piping under the clothes and heated by a gas-powered soldering iron


(86) PCT/IB2004/051800 (87) WO2005/055751
 (51) IPC7:F23D21/00; F28D21/00; B62J33/00; A41D13/005
 (71) Sandor Szekeley; Gabor Pusztay
 (72) Pusztay, Gabor; Szekeley, Sandor;
 (31) 03 0300296 (32) 5 Dec 2003 (33) HU
 (74) WATERMARK PATENT & TRADE MARK ATTORNEYS, Level 2, 302 Burwood Road, Hawthorn, Victoria 3122, Australia
 (57) An apparatus for temperature modification, associated with garments or similar protective gear connected to, and in part covering, the body of a living creature, in particular a human being, and equipped with a heat energy generating device and heat exchange equipment in thermal contact with it, providing heat energy to the body or withdrawing the same from it, the heat-exchange device is an inlay designed as a flexible piping 1, including and transporting a liquid heat transmitting medium, fixed as a pipe-coil 1 under the inner lining of the clothing, whereas the heat transmitting medium consists of water and/or anti-freezing liquid, conducted through a passage of a heat-exchange block formed within and arranged in a housing 3 that is thermally insulated from the environment, wherein the heat generating device is a small-size portable propane-butane burner in the form of a gas-powered soldering iron, linked to one side of the water/air heat exchange block.



(21) 548229 (22) 14 Jan 2005
 (54) Integrase fusion proteins and their use with integrating gene therapy
 (86) PCT/GB2005/000115 (87) WO2005/068641
 (51) IPC7:A61K38/00; C12N15/62,867
 (71) ARK THERAPEUTICS LTD.
 (72) Ahlroth, Mervi; Schenkwein, Diana; Airene, Kari; Yla-Herttuala, Seppo; Laitinen, Olli;
 (31) 04 0400814 (32) 14 Jan 2004 (33) GB
 (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand
 (57) Disclosed is an in vitro method of targeting integration of a transgene comprising retrovirus-like nucleic acid into a eukaryotic genome, in which the genome is targeted by a restriction enzyme that bind nucleic acid and the transgene is introduced at the binding site, wherein the endonuclease is specific to a site in an abundant rDNA locus and is fused to an integrase that mediates the introduction of the transgene.


(21) 548246 (22) 11 Aug 2004
 (54) Surgical mallet with a cylindrical head and recess for extraction of Kirschner wires and other segical connectors
 (86) PCT/IB2004/002601 (87) WO2005/055845
 (51) IPC7:A61B17/88,92
 (71) Synthes GmbH
 (72) Buttler, Markus; Streff, Patrick;
 (31) 03 2083 (32) 8 Dec 2003 (33) CH
 (74) SPRUSON & FERGUSON, GPO Box 3898, Sydney, NSW, 2001, Australia
 (57) A surgical mallet (1c) is disclosed. The surgical mallet (1c) has a head (2d) of a substantially cylindrical shape and provided with at least one recess (6d) in which a device (17d) for inserting and/or extracting implants, in particular intramedullary nails and Kirschner wires, can be received.

According to the invention, the recess (6d) comprises at least two separate zones, namely an insertion channel (7d) and a locking chamber (9d) in which the insertion and/or extraction device (17d) can be locked. Moreover the base (5d) of the mallet head is self-contained.




(21) 548327 (22) 5 Jan 2005
 (54) Memantine for the treatment of mild and mild-to-moderate alzheimer's disease
 (86) PCT/US2005/000145 (87) WO2005/067908
 (51) IPC7:A61K31/13; A61K45/06
 (71) MERZ PHARMA GMBH & CO. KGAA
 (72) McDonald, Scott; Gergel, Ivan; Potkin, Steven; Stoffler, Albrecht; Moebius, Hans-Joerg; Wirth, Yvonne;
 (31) 04 534553 (32) 5 Jan 2004 (33) US
 (31) 04 542176 (32) 4 Feb 2004 (33) US
 (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand
 (57) Disclosed is a use of memantine or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating mild to moderate alzheimer's disease, wherein the medicament is manufacture for administration of memantine at an initial dose of 5 mg/day rising weekly by 5 mg/day to a final dose of 20 mg/day.

(21) 548485 (22) 30 Dec 2004
 (54) Device for enabling access to a structure above ground level
 (86) PCT/DK2004/000930 (87) WO2005/064152
 (51) IPC7:F03D1/00; E04G3/10
 (71) PP Energy ApS
 (72) Teichert, Paul;
 (31) 03 01955 (32) 30 Dec 2003 (33) DK
 (31) 04 00737 (32) 8 May 2004 (33) DK
 (74) IP Gateway Patent and Trademark Attorneys, Suite 2, 18 Carol Avenue, Springwood, Brisbane, Queensland 4127, Australia
 (57) A device for enabling access to a rotor blade 254 of a wind turbine by lowering and/or lifting the device in relation to the wind turbine, the device comprising a first endless frame structure 250 defining an opening, wherein at least part of the first endless frame structure 250 forms a track portion, the track portion being adapted to guide, in relation to the track portion, a movable object 257 along the track portion, the device further comprising an arrangement for aligning the rotor blade 254 of the wind turbine with the opening defined by the first endless frame structure 250.



- (21) 548506 (22) 31 Dec 2004
 (54) Process for preparing 5-chloro-N-(((5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl)methyl)-2-thiophenecarboxamide
 (86) PCT/EP2004/014870 (87) WO2005/068456
 (51) IPC7:C07D409/14
 (71) Bayer HealthCare AG
 (72) Berwe, Mathias; Thomas, Christian; Rehse, Joachim; Grotjohann, Dirk;
 (31) 04 04002044 (32) 15 Jan 2004 (33) DE
 (74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand
 (57) Disclosed is a process for preparing 5-chloro-N-(((5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl)methyl)-2-thiophenecarboxamide, (formula (I)) by reacting 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one hydrochloride with 5-chlorothiophene-2-carbonyl chloride, in a solvent chosen from ether, alcohol, ketone, water, or a mix of these, and with the use of an organic base.




- (21) 548702 (22) 7 Jan 2005
 (54) Antibodies to MAdCAM
 (86) PCT/US2005/000370 (87) WO2005/067620
 (51) IPC7:C07K16/28
 (71) Pfizer Inc.; Amgen Fremont Inc.
 (72) Pullen, Nicholas; Molloy, Elizabeth; Kellermann, Sidrid-Aimee; Green, Larry L; Haak-Frendscho, Mary;
 (31) 04 535490 (32) 9 Jan 2004 (33) US
 (74) CULLEN & CO., Level 32, 239 George Street, Brisbane, QLD 4000, Australia
 (57) Disclosed is human monoclonal antibody or an antigen-binding portion thereof that specifically binds to human Mucosal Addressin Cell Adhesion Molecule (MAdCAM), wherein: (a) the heavy chain comprises the heavy chain CDR1, CDR2 and CDR3 amino acid sequences of a reference monoclonal antibody selected from the group consisting of: 1.7.2, 1.8.2, 6.14.2, 6.22.2, 6.34.2, 6.67.1, 6.73.2, 6.77.1, 7.16.6, 7.20.5, 7.26.4, 9.8.2, 6.22.2-mod, 6.34.2-mod, 6.67.1-mod, 6.77.1-mod, and 7.26.4-mod; (b) the light chain comprises the light chain CDR1, CDR2 and CDR3 amino acid sequences of a reference monoclonal antibody selected from the group consisting of: 1.7.2, 1.8.2, 6.14.2, 6.22.2, 6.34.2, 6.67.1, 6.73.2,

6.77.1, 7.16.6, 7.20.5, 7.26.4, 9.8.2, 6.22.2-mod, 6.34.2-mod, 6.67.1-mod, 6.77.1-mod, and 7.26.4-mod; (c) the antibody comprises a heavy chain of (a) and a light chain of (b); or (d) the antibody is the antibody of (c), wherein the heavy chain and light chain CDR amino acid sequences are selected from the same reference monoclonal antibody.

- (21) 548713 (22) 12 Jan 2005
 (54) Ice cream and ice cream formulations containing maltitol
 (86) PCT/US2005/000960 (87) WO2005/070183
 (51) IPC7:A23G9/00
 (71) Corn Products International, Inc.
 (72) Deis, Ronald C; Kuenzle, Charles E; Tharp, Bruce W;
 (31) 04 536062 (32) 13 Jan 2004 (33) US
 (74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand
 (57) Disclosed is an ice cream formulation comprising: a) fat in an amount of from 6 to 15% by weight, based on the total weight of the ice cream formulation; b) non-fat milk solids in an amount of from 6 to 12% by weight, based on the total weight of the ice cream formulation; and c) maltitol in an amount from 30 to 45% by weight on a dry solids basis.

- (21) 548760 (22) 2 Feb 2005
 (54) Flat plate heat exchanger coil and method of operating and cleaning the same
 (86) PCT/CA2005/000122 (87) WO2005/075915
 (51) IPC7:F28D9/00; F28G13/00; F28F3/00
 (71) PETER DAWSON
 (72) Dawson, Peter;
 (31) 04 775381 (32) 10 Feb 2004 (33) US
 (74) DON HOPKINS & ASSOCIATES, Level 12, Forsyth Barr House, Johnston Street, Wellington 6011, New Zealand
 (57) A flat heat exchanger plate typically used in a bulk material heat exchanger is provided. The flat heat exchanger plate is designed to operate under a negative internal pressure to eliminate depressions or dimples that are typically formed into the sides of these types of heat exchanger coils during the manufacture process. With the removal of the depressions or dimples the tendency for bulk material to accumulate to the exterior surface of the plate is reduced, thereby increasing the service period of the plate. The flat plate is also provided with methods of automated cleaning of the plate coil, such as applying a low positive internal pressure in a cyclic manner to dislodge material accumulated on the coil, bumping the coil to causing a shock wave through the coil or providing means to create a shearing effect between adjacent coils to dislodge material accumulated on the exterior of the coil.



(21) 548803 (22) 3 Jan 2005

(54) Systems, methods, software and interfaces for integration of case law with legal briefs, litigation documents, and/or other litigation-support documents

(86) PCT/US2005/000042 (87) WO2006/083241

(51) IPC7:G06F17/30; G06Q50/00

(71) Thomson Reuters Global Resources

(72) Anderson, Steven B;

(31) 03 533860 (32) 31 Dec 2003 (33) US


(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) A system for the integration of case law with legal briefs, litigation documents, and/or other litigation-support documents comprises a server for an online legal-research provider with the server coupled to one or more databases; a client access device coupled to the server via the Internet and having a display for presenting a graphical user interface including one or more user-interface elements at least partially configured or defined by the server and a means associated with the server for returning search results to the client access device in response to the submitted legal-research query.

The one or more of the user-interface elements provide a single-display area including a profiler-query portion, a litigation-valuation-query region, a negotiation-research portion, a brief-bank-and-depositions-transcript portion, a court-docket portion, a court-rules-portion, a forms-and-check-lists portion, and a procedure-and-evidence portion; and one or more of the elements provide a query portion that allows the user to define and submit one or more legal-research queries.

The search results include a first set of first documents and associated first user-interface elements. The first set of documents includes or identifies one or more case law documents and at least one of the first user-interface elements presents an option for the user to retrieve one or more litigation support documents related to one or more of the case-law documents.

Divisional filed as 571889



(21) 548871 (22) 30 Jan 2005

(54) Use of arylsulfatase A for treating metachromatic leukodystrophy

(86) PCT/DK2005/000068 (87) WO2005/073367

(51) IPC7:C12N9/16; A61K38/46; A61P25/28

(71) Shire Pharmaceuticals Ireland Limited

(72) Fogh, Jens; Andersson, Claes; Weigelt, Cecilia; Moller, Christer; Hyden, Pia;

(31) 04 00144 (32) 30 Jan 2004 (33) DK

(31) 04 540061 (32) 30 Jan 2004 (33) US

(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) Disclosed is the use of a formulation comprising an effective amount of arylsulfatase A for the manufacture of a medicament for reducing the levels of galactosyl sulphatide in cells within the central nervous system in a subject suffering from and/or being diagnosed with metachromatic leukodystrophy, wherein said formulation is to be administered by intravenous or subcutaneous administration.

Divisional filed as 576986

(21) 548990 (22) 7 Feb 2005

(54) Anti-CD38 human antibodies and uses therefor

(86) PCT/IB2005/002476 (87) WO2005/103083

(51) IPC7:C07K16/00

(71) MORPHOSYS AG

(72) Tesar, Michael; Jager, Ute;

(31) 04 541911 (32) 6 Feb 2004 (33) US

(31) 04 547584 (32) 26 Feb 2004 (33) US

(31) 04 553948 (32) 18 Mar 2004 (33) US

(31) 04 599014 (32) 6 Aug 2004 (33) US

(31) 04 614471 (32) 1 Oct 2004 (33) US

(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand

(57) Disclosed is an isolated human or humanized antibody or functional fragment thereof comprising an antigen-binding region that is specific for an epitope of CD38 (SEQ ID NO: 22), wherein said antibody or functional fragment thereof is able to mediate killing of a CD38+ target cell by ADCC with an at least five-fold better efficacy than chimeric OKT10 (SEQ ID NOs: 23 and 24) under the same or substantially the same conditions when a human PBMC cell is employed as an effector cell, wherein said CD38+ target cell is selected from the group consisting of LP-1 (DSMZ: ACC41) and RPMI-8226 (ATCC: CCL-155), and wherein the ratio of effector cells to target cells is between about 30:1 and about 50:1.

(21) 549029 (22) 7 Aug 2006 (23) 7 Aug 2007

(54) An engineered wood construction system for high performance structures using pre-stressed tendons and replaceable energy dissipaters

(51) IPC7:E04H9/02; E04B1/26,38,98; E04C3/18,42,292


(71) PRESTRESSED TIMBER LIMITED

(72) Buchanan, Andrew; Pampanin, Stefano; Palermo, Alessandro;


(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) An energy absorbing system for a building is disclosed. The system includes at least one connection (T) between an engineered wood load bearing element (P) of the building and another load bearing element (P) or a foundation of the building (F). The connection (T) has at least one high tensile strength tendon tying the load bearing elements (P) or the load bearing element (P) and the foundation (F) together. The connection (T) is in tension to pre-stress the connection (T) while allowing controlled relative movement between the load bearing elements (P) or the load bearing element (P) and the foundation, during a loading event. One or more energy dissipaters (D, E) are replaceably connected between the load bearing elements (P) or load bearing element (P) and the foundation (F), which will absorb energy from a loading event (Z) causing relative movement of the connection (T).


Divisional filed as 576218




(21) 549052 (22) 9 Aug 2006 (23) 7 Aug 2007
 (54) Storage unit for trailer or vehicle tray with scissor lift to raise and lower a storage compartment
 (51) IPC7:B60P1/02; B60R9/00; B60R11/06; B62D33/02,04
 (71) DECKMATE LIMITED
 (72) MacDonald, Andrew William;
 (74) P L BERRY & ASSOCIATES, 61 Cambridge Terrace, Christchurch 8013, New Zealand
 (57) A storage unit for a trailer or light commercial vehicle that can securely hold and organise cargo is disclosed. The unit is dimensioned to fill the trailer or vehicle tray area (1) and consists of a storage compartment (4) and a low-profile scissors lift (5) to move the compartment between a lowered and a raised position. In the raised position the compartment is lifted above the side walls (3) of the trailer or tray so that the compartment can be accessed. A top cover (8) which completely covers the trailer or tray area may be fitted to the compartment.




(21) 549054 (22) 8 Aug 2006 (23) 8 Aug 2007
 (54) Chain wheel with a number of chain link pockets
 (51) IPC7:B66D1/72,74; F16H55/00,30
 (71) VETUS N.V.
 (72) Hsien-Juey, Chiu;
 (74) BALDWIN'S INTELLECTUAL PROPERTY, Level 14, Baldwin's Centre, 342 Lambton Quay, Wellington 6011, New Zealand
 (57) A chain wheel part comprising: a centre about which the part is adapted to rotate in use; and a plurality of chain link receiving pockets, wherein each pocket is bounded by a wall at first and second ends and is shaped such that a first end 20 of a chain link received in the pocket in use is nearer the centre of the chain wheel part than a second end 22 of the chain link.



(21) 549526 (22) 1 Mar 2002
 (54) Human skin equivalents comprising near diploid immortalized keratinocyte cells (NIKS)
 (51) IPC7:C12Q1/68; A61L27/00; C12N5/10; G01N33/50; C12N5/06; G01N33/15; C12N15/09; C12N5/02
 (71) STRATATECH CORPORATION
 (72) Comer, Allen; Allen-Hoffmann, Lynn; Hoffmann, Michael; Conrad, Paul Barth; Ivarie, Cathy Ann-Rasmussen;
 (31) 01 273034 (32) 2 Mar 2001 (33) US
 (31) 01 287898 (32) 1 May 2001 (33) US
 (74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand
 (57) Disclosed is a composition comprising a pre-graft human skin equivalent, said skin equivalent having a surface electrical capacitance of from about 40 to about 240 pF measured as the difference in reading over a 10 second interval, said skin equivalent having a combined content of ceramides 5, 6, and 7 in said skin equivalent of from about 20 to about 50% of total ceramide content, wherein said pre-graft skin equivalent comprises Near Diploid Immortalized Keratinocyte cells, and a method of screening for cellular toxicity using said skin equivalent.
 (62) Divided out of 528166



(21) 549855 (22) 12 Sep 2006 (23) 12 Dec 2007
 (54) Improvements in screens and methods of their manufacture
 (51) IPC7:E04D13/076; B29C45/00
 (71) MARLEY NEW ZEALAND LIMITED
 (72) Forrester, Neil; Williams, Michael; McKee, John;
 (74) BALDWIN'S INTELLECTUAL PROPERTY, Level 14, Baldwin's Centre, 342 Lambton Quay, Wellington 6011, New Zealand
 (57) Screens with particular application as filters in a downpipe, and methods for their manufacture are disclosed. The screen (1) has a plurality of channels (7) that pass from an upstream side to a downstream side, where the openings of the channels on the upstream side are larger than the openings of the respective channels on the downstream side. More than 50% of the surface area of the upstream side is occupied by channel openings. In use, the screen is positioned on an incline in a fluid flow to separate out debris from the flow.



(21) 549898 (22) 18 Mar 2005

(54) Optimized expression of HPV 52 L1 in yeast

(86) PCT/US2005/009199 (87) WO2005/097821

(51) IPC7:C07K14/025

(71) Merck & Co., Inc.

(72) Bryan, Janine T; Brownlow, Michelle K; Schultz, Loren D; Jansen, Kathrin U;

(31) 04 555926 (32) 24 Mar 2004 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed are synthetic DNA molecules encoding modified variants of the human papillomavirus protein HPV52 L1. Specifically, the present disclosure provides polynucleotides encoding HPV 52 L1 protein, wherein said polynucleotides are codon-optimized for high level expression in a yeast cell. Further disclosed are synthetic nucleotide molecules that are altered to eliminate transcription termination signals that are recognized by yeast. The synthetic molecules may be used to produce HPV52 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV52 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity and may also be useful for treatment of existing HPV infections.

(21) 549928 (22) 22 Mar 2005

(54) Process for producing cheese

(86) PCT/DK2005/000197 (87) WO2005/089562

(51) IPC7:A23C19/032,04

(71) NOVOZYMES A/S; Novozymes North America, Inc.; Chr. Hansen A/S

(72) Fatum, Tine Muxoli; Higgins, Don;

(31) 04 555922 (32) 24 Mar 2004 (33) US

(74) BALDWIN'S INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) Disclosed is a process for increasing cheese yield comprising adding to cheese milk, or a fraction of cheese milk, a phospholipase selected from the group consisting of phospholipase C, phospholipase D, and combinations thereof; and producing cheese from the cheese milk.

(21) 550000 (22) 14 Apr 2005

(54) Ultrasonic curing of dental filling materials

(86) PCT/DK2005/000258 (87) WO2005/099652

(51) IPC7:A61K6/027,083

(71) Dentofit A/S

(72) Van Lelieveld, Alexander; Almdal, Kristoffer; Linderorth, Soren; Sorensen, Bent Fruerlund;

(31) 04 562246 (32) 15 Apr 2004 (33) US

(31) 04 0400592 (32) 15 Apr 2004 (33) DK

(31) 04 0401188 (32) 5 Aug 2004 (33) DK

(31) 04 598893 (32) 5 Aug 2004 (33) US

(31) 05 0500201 (32) 10 Feb 2005 (33) DK

(74) F B RICE & CO, Level 23, 44 Market Street, Sydney, New South Wales 2000, Australia

(57) The disclosure relates to a composite material exhibiting a low or even negligible volumetric shrinkage upon curing, or even a small expansion (e.g. up to 0.5%), in particular composite materials in the form of dental filling materials, wherein the composite material comprises one or more fillers and a polymerizable resin base, wherein said one or more fillers comprise at least one filler ingredient, said filler ingredient(s) includes metastable zirconia in the tetragonal or cubic crystalline phase, said filler ingredient(s) being present in a metastable first phase and being able to undergo a martensitic transformation to a stable second phase, the volume ratio between said stable second phase and said metastable first phase of said filler ingredient(s) being at least 1.005. The disclosure also relates to a method of controlling volumetric shrinkage of a composite material upon curing, and to a method of reconstructing a tooth. The disclosure further relates to a population of zirconia particles and methods for preparing such zirconia particles (e.g. zirconia in the tetragonal phase or zirconia in the cubic phase). The martensitic transformation of the filler ingredients is triggered by application of ultrasound or by a chemical trigger.

(21) 550085 (22) 12 May 2005

(54) Monoazo dyes

(86) PCT/IB2005/001465 (87) WO2005/113683

(51) IPC7:C09B43/24; C09D11/02


(71) Clariant Finance (BVI) Limited

(72) Schoefberger, Georg; Daettwyler, Urs;

(31) 04 04011856 (32) 19 May 2004 (33) EP

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Provided are specified derivatives of C.I. Acid Orange 67, useful for dyeing and/or printing organic substrates and for producing printing inks for the InkJet process.



(21) 550087 (22) 24 Mar 2005

(54) Imidazole compounds

(86) PCT/US2005/009715 (87) WO2005/092066

(51) IPC7:C07D401/02,12,14; C07D403/12; C07D405/14; A61K31/417; A61P37/00; A61P17/00



(71) JANSSEN PHARMACEUTICA N.V.

(72) Buzard, Daniel J; Edwards, James P; Kindrachuk, David E; Venable, Jennifer D;

(31) 04 556356 (32) 25 Mar 2004 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed are an imidazole compound of formula (I) or (II), and a pharmaceutical composition comprising the imidazole compounds for treating or preventing inflammatory and H4 receptor-mediated conditions, and inhibiting leukocyte recruitment.



(21) 550106 (22) 21 Apr 2005

(54) Transgenic animals and uses thereof

(86) PCT/US2005/013618 (87) WO2005/104835

(51) IPC7:A01K67/027; C07K16/00; C12N15/00; C12P21/00

(71) Kyowa Hakko Kirin Co., Ltd.

(72) Robl, James; Kuroiwa, Yoshimi; Kasinathan, Poothappillai; Ishida, Isao; Tomizuka, Kazuma;

(31) 04 564458 (32) 22 Apr 2004 (33) US

(31) 04 564445 (32) 22 Apr 2004 (33) US

(31) 05 657186 (32) 28 Feb 2005 (33) US

(74) Pizzeys Patent and Trade Mark Attorneys, Level 2, Woden Plaza Offices, Woden Town Square, Woden, ACT 2606, Australia

(57) Disclosed is a transgenic ungulate whose genome comprises mutations in two different unrearranged IgM heavy chain loci, said ungulate producing less endogenous IgM heavy chain loci, said ungulate producing less endogenous IgM heavy chain than a control ungulate lacking the mutation.

(21) 550289 (22) 4 Oct 2006 (23) 3 Oct 2007

(54) Fire suppression system with spray nozzles fed from water supply to faucet on sensing fire

(51) IPC7:A62C3/00; A62C2/00; A62C37/00; G08B17/00


(60) 556140

(71) Benjamin Adair Munro

(72) Munro, Benjamin;

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) A fire suppression system includes a faucet, a spout and one or more spray nozzles with a first valve operable into an open position to fluidly couple the spout to a water supply for the faucet, a second valve operable into an open position to fluidly couple the spray nozzle(s) to a water supply from the faucet and a fire sensor connected to a controller where upon sensing a fire the sensor outputs a signal to trigger the second valve into an open position.



(21) 550336 (22) 11 Mar 2005

(54) A process and a device for conveying odd-shaped containers, typically soft drink bottles

(86) PCT/US2005/008374 (87) WO05/087628

(51) IPC7:B65B1/04

(71) GRAHAM PACKAGING COMPANY, L.P.

(72) Sheets, Philip; Kelley, Paul; Denner, John;

(31) 04 551772 (32) 11 Mar 2004 (33) US

(74) Pizzeys Patent and Trade Mark Attorneys, Level 2, Woden Plaza Offices, Woden Town Square, Woden, ACT 2606, Australia

(57) A process for efficiently conveying containers along a table-top conveying system includes the steps of temporarily securing a transfer stabilizing support (1a, 1b) to a bottom end of a formed container (14) so that the container can freely move along a production line using the table-top conveying system where the transfer stabilizing support has a bottom surface with an opening, a sidewall extending substantially perpendicular to the bottom surface, and a ridge area surrounding the opening and inside the sidewall of the support; and after the container has gone through operations of the production line, the transfer stabilizing support is removed so that aesthetic qualities of the formed container shape are revealed.




FIG. 4

(21) 550354 (22) 27 May 2004

(54) Mesh and methods and apparatus for forming and using mesh

(86) PCT/NZ2004/000104 (87) WO2005/115659

(51) IPC7:B21L19/00; B21L5/00,02; B22D19/00,04; B22D25/00,02

(71) Kaynemaile Limited

(72) Horsham, Kayne Bruce;

(74) ELLIS VERBOEKET TERRY, Level 12, Forsyth Barr House, Johnston Street, Wellington, New Zealand

(57) A method of forming a mesh comprising: a. providing a plurality of link elements 1 2 3 4; and b. moulding a plurality of link elements 5 through the link elements so as to interconnect the link elements to form a continuous mesh of interconnected link elements.

